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established drug target by various screening methods such as NMR, X-Ray 
Crystallography and Biochemical Assays. Trypanosoma brucei cyclic nucleotide 
phosphodiesterase B1 (TbrPDEB1) is a validated drug target reported to be essential in the 
life cycle of the Trypanosoma brucei parasite ± the causative agent of Human African 
Trypanosomiasis, one of several Neglected Parasitic Diseases which affects 
underdeveloped countries, and in some cases even First World countries. Otherwise known 
as Sleeping Sickness, the insect-borne parasitic disease occurs in 36 sub-Saharan African 
countries. The estimated mortality rate is up to 500,000 deaths per year and up to 80 
million people are at risk of infection. With current methods of treatment being limited, 
ineffective and in some cases unsafe, there is an urgent need for new, more effective and 
safer medication.  
 
In this research project, the TbrPDEB1 catalytic domain construct plasmid (provided by 
the host laboratory at the University of Kent) was used to transform an established E. coli 
bacteria strain for the purpose of protein expression. A small fragment library put together 
by IOTA Pharmaceuticals consisting of 31 active human PDE inhibitors was initially 
validated by Proton NMR and used to soak TbrPDEB1 protein crystals. Ligand uptake was 
determined by X-Ray diffraction at the Diamond Light Source. Through the use of the 
three previously mentioned screening approaches, fragment binders to the TbrPDEB1 
target enzyme were identified. Additionally, inhibition of the fragment binders to the target 
was also measured and assessed in comparison to NPD-008, a known TbrPDEB1 inhibitor 
of moderate potency. Out of the 31 fragments, one fragment was identified as an optimal 
binder and low potency inhibitor to TbrPDEB1, which underwent a similarity search 
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1 Introduction 
Since the dawn of time, mankind has continuously shared a common instinct throughout 
the decades ± survival. In modern times, the development and understanding of medicinal 
practice in combination with advanced technology has greatly supported our most basic 
instinct, with key scientific discoveries such as Penicillin, Germ Theory and DNA 
alongside major research projects such as the Human Genome Project gifting mankind an 
extended average lifespan of 30 years1. Despite this, illness and disease remain a great 
issue in many regions of the world, particularly in underdeveloped countries lacking proper 
sanitation and healthcare services. Hence, new research and further ground-breaking 
discoveries in drug development continue to be pursued in endless topics of medicinal 
treatment, thuVFRQWLQXLQJWRDLGDQGVXSSRUWPDQNLQG¶VVXUYLYDO7KHWRSLFRILQWHUHVWLQ
the case of this research project is based on neglected parasitic diseases (NPDs). 
 
1.1 Neglected Parasitic Diseases 
$SDUDVLWLFGLVHDVHLVWLHGZLWKWKHWHUPµQHJOHFWHG¶ZKHQFRQWULEXWLQJLQYHVWPHQWVIRU
controlling said disease are extremely low considering the health impact it has on human 
life. This impact causes most damage in underdeveloped countries lacking proper 
sanitation and access to public health care services; however, this is not to say that 













































Taeniasis Trachoma Yaws 
Table 1: 
Known NPDs2 
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A table listing known NPDs can be seen in Table 1 on the previous page, interpreted from 
the World Health Organisation (WHO)2. NPDs of interest in this project are seen 
highlighted in red. 
 
Chagas disease, otherwise known as American trypanosomiasis is a NPD caused by the 
parasitic kinetoplastid Trypanosoma cruzi, or Tcr. American trypanosomiasis affects 6 to 7 
million people worldwide, most of which are located in Latin America - the location of 
origin of the Tcr parasite3. For a long time, the parasite was confined to the Latin America 
region carried in a vector being the Triatominae insect. The vector-borne parasite is 
transmitted to hosts following a blood meal. The lack of symptoms and non-specific 
manifestations in the acute phase of this parasitic disease allows it to remain unnoticed and 
spread in the body by infecting cells and muscle tissue, eventually leading to serious 
chronic health issues such as cardiomyopathy within 20 to 30 years following infection. A 
2016 research paper estimates around 1 million people were infected by the parasite in 
2006 in Mexico, with an additional risk of infection of up to 29.5 million people4. In recent 
years, Chagas disease has become a worldwide issue due to the urban migration and spread 
of the parasite from rural and underdeveloped areas5. Being a NPD, migration can occur in 
multiple ways, such as congenital transmission, organ transplantation, and especially the 
transfusion of contaminated blood which can quickly spread even in developed countries 
due to the inability to diagnose Chagas disease in patients as a result of clinical 
unawareness. Hence, the number of people infected by the NPD has risen greatly in the last 
decade, with an estimate of more than 300,000 people living in the United States being 
infected6. Current therapies for Chagas disease treatment are limited and no effective 
vaccines are available, emphasising the importance and urgent need for effective treatment. 
Chagas Disease is just one example of Neglected Parasitic Diseases ± another being 
African Trypanosomiasis, the main focus in this research project.  
 
1.2 African Trypanosomiasis 
Like Chagas Disease, African trypanosomiasis is a NPD caused by the same parasitic 
kinetoplastid genus ± Trypanosoma, a monophyletic group of unicellular parasitic 
flagellate protozoa7. The Trypanosoma brucei parasite species is the causative agent of 
African trypanosomiasis, otherwise known as µ6OHHSLQJVLFNQHVV¶± one of the most 
important but equally most neglected parasitic diseases known to impact more than 70 
million people13. Most commonly found in rural areas of sub-Saharan Africa10, Human 
African trypanosomiasis (HAT) exists in two different forms caused by morphologically 
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indistinguishable subspecies of T. brucei8. The parasite is transmitted to humans through 
the bite of numerous different species of the Tsetse fly vector: T brucei gambiense is found 
in West and Central Africa, whilst T brucei rhodesiense is more common in the Eastern 
and Southern regions of Africa8,9 ± the former of these subspecies accounting for 97% of 
reported cases of HAT12; These are the main forms of sleeping sickness with varying 
clinical presentations that infect humans, as seen mapped out in Figure 1 - interpreted from 


















Animals can also host these forms of parasite and can act as parasitic reservoirs for 
uninfected tsetse flies, allowing the disease to quickly manifest and spread in areas at risk. 
A third pathogenic subspecies of the T brucei parasite, T brucei brucei is known to cause 
Animal trypanosomiasis, otherwise known as nagana. Nagana affects wild and domestic 
animals alike and therefore causes further impact on economic and agricultural 
development in Africa11 due to the loss of meat and milk production from infected and 
chronically ill cattle. HAT evolves through clinically distinct stages, with the initial 
symptoms of fever being non-specific to the disease and therefore making it difficult to 
diagnose ± a common trait in NPDs also seen in Chagas disease. Trypanosomal chancre, a 
skin reaction caused by the immediate bite of an infected tsetse fly is seen in the faster 
progressing East African trypanosomiasis, making the disease somewhat more 
Figure 1: 
Mapped distribution of T brucei subspecies in 201010 
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distinguishable compared to the more inconspicuous, slower acting West African 
trypanosomiasis8 variation.  
 
During the primary stages of infection, an increased severity of fever, headaches and joint 
pains is seen in patients as the trypanosomes enter the lymphatic system and mature into 
the Trypomastigotes VWDJH/\PSKDGHQRSDWK\RUµ:LQWHUERWWRP¶VVLJQ¶± an abnormal 
inflammation of the lymph nodes as a result of parasitic growth is a common characteristic 
seen in the early stages of HAT8,12. Trypomastigotes accumulated in the lymph nodes 
multiply by binary fission and enter the bloodstream, soon passing the blood brain barrier14 
and infecting the central nervous system; Figure 2 depicts the accumulation of 
Trypomastigotes in red blood cells. This second, neurological encephalopathy stage is 
where symptoms of the disease become most apparent, and the stage at which death is 
imminent if no method of treatment is provided.  
Changes of behaviour, lethargy and confusion are common in this stage of infection, as 















Leading up to modern times, three severe sleeping sickness epidemics occurred in Africa 
in the 20th century ± with the first lasting 8 years until 1906 and resulting in the deaths of 
800,000 people15 in Uganda and Kenya ± with the colonisation of Africa creating optimal 
disease spreading conditions due to poor healthcare, lack of sanitation and famine. A 
second epidemic was seen in the 1920s, which eventually subsided and led to the decline 
Figure 2: 
Diagram showing the accumulation of Trypomastigotes in red 
blood cells8,52 
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of sleeping sickness in Sub-Saharan Africa by 60%15 due to the development of early 
forms of treatment against sleeping sickness including Suramin and an organo-arsenic 
based tryparsamide (later developed into Melarsoprol) which was used to combat the 
second-stage infection of both HAT15 variations. Pentamidine ± an antimicrobial - was 
eventually developed in 1937 and was used to treat first stage west African 
trypanosomiasis8, with Suramin being used against the East African variant. Numerous 
methods of vector control such as bush clearing, destruction of parasitic reservoirs such as 
infected cattle and game animals, and the used of the DDT 
(dichlorodiphenyltrichloroethane) insecticide (several years after its discovery in 193915) 
also contributed greatly to the drastic NPD decline, leading to an all-time low of under 
10,000 reported cases in 196015. This however was short lived, as the disease once again 
began to spread at an increasing rate by the mid-1970s, eventually leading to the third and 
most recent epidemic in the 1990s with 500,000 reported cases up until 201515,17. This can 
be seen in Figure 3 below - a graph depicting the number of reported cases of sleeping 
sickness and population screened between 1939-2004, interpreted from a 2008 review 
article on the history of the relevant NPD by D. Steverding15,16. 
The rapid decolonisation of Africa following World War II led to political instability in 
many African countries, resulting in neglect of health services and in turn an ignorance to 
the sleeping sickness disease15. In combination with a lack of support from new 
governments, screening programs and parasitic control methods gradually declined as seen 
circled in red in Figure 3, leading to neglect of sleeping sickness endemic countries and a 











Number of reported cases of sleeping sickness (grey columns) and population screened 
for the disease (black circles) between 1939-200415,16 
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In recent years, the increased awareness of the NPD as a result of a WHO campaign in 
2015 which donated necessary drugs to be distributed in affected countries17 increased 
patient screening and disease diagnosis, and continued methods of vector control have 
helped increase control over the disease and reduce the overall spread and reported cases. 
Despite an estimate of 20,000 reported cases, the number of people affected are still high, 
with an even greater number of 65 million people still at risk of infection. Current forms of 
treatment still include those previously mentioned; Pentamidine and Suramin are relatively 
safe drugs with little side effects and continue to be used to treat first-stage sleeping 
sickness, however some cases of pathogenic resistance of the latter drug have been 
reported18,19. Melarsoprol is still one of the only drugs used for second-stage sleeping 
sickness treatment despite causing many side effects and sometimes cases of reported 
toxicity to humans, even proving to be fatal in up to 10% of cases12. Eflornithine20 is 
another form of treatment less toxic than Melarsoprol, however it is much more difficult to 
administer to a patient, making it an unreliable treatment choice. Repeated treatment over a 
period of 8-10 days is also required, with second-stage cases including hospital admission 
and intensive patient monitoring, therefore also demanding a high degree of expertise and 
required training for the treatment of patients8.  
 
Hence, current methods of treatment have proven to be undesirable, difficult to use and in 
some cases unsafe. There is an urgent need for novel, safer and more effective medication 
for the treatment of HAT. Recent studies established the role of cyclic nucleotide 
phosphodiesterase (PDE) enzymes in the life cycle of the Trypanosoma brucei parasite. 
The importance of this enzyme in parasitic functionality makes it a promising research 
drug target for the treatment of HAT. 
 
1.3 Parasitic Phosphodiesterases (PDEs) 
Phosphodiesterases, or PDEs comprise a group of enzymes capable of catalysing the 
hydrolysis of secondary messenger molecules cyclic adenosine monophosphate (cAMP) 
and cyclic guanosine monophosphate (cGMP) to adenosine monophosphate (AMP) and 
guanosine monophosphate (GMP) respectively, following the degradation of a 
phosphodiester bond21. The reaction scheme (drawn using chemsketch68) can be seen in 
Figure 4 on the following page, adapted from a study by F. Svennson, A. Bender and D. 
Bailey22: 















The secondary cyclic nucleotide messenger molecules cAMP and cGMP are important in 
mediation of biological responses, and are essential in hormone regulation,  
neurotransmitters, protein signalling and cell proliferation and differentiation21. At high 
cyclic nucleotide concentrations, protein kinases A and G (dependent on cAMP and 
cGMP, respectively) are activated in eukaryotes, resulting in the phosphorylation of 
numerous substrate protein. The phosphorylation of these substrates is vital in a number of 





Reaction scheme showing PDE catalysis of cAMP substrate to AMP22 
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Similarly, a second reaction scheme shown in Figure 523 shows the synthesis of cAMP 
from ATP, catalysed by an adenyl cyclase (AC) enzymes. Both reaction scheme described 
in Figure 4 and Figure 5 aid in regulating the level of secondary messengers and are 
therefore essential for most cellular processes and intracellular signalling. PDE enzyme 
inhibitors would block this reaction pathway, resulting in high levels of cyclic nucleotide 
build up due to the inability of catalytic breakdown via hydrolysis and hence a disturbance 




Parasitic PDE phenotypes can be classed into differing families of genes present in all 
kinetoplastid genomes; Four genetically distinct PDE families exist known as PDE A-D24. 




Reaction scheme showing AC catalysis of ATP substrate to cAMP23 
Figure 6: 
Trypanosoma brucei parasitic PDEs 
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Figure 6 gives a brief overview of the sequence differentiation in the 4 presented Tbr PDE 
forms. As can be seen, each family varies in terms of amino acid residues in the case of the 
full-length sequence, and also in types of protein domains; TbrB is seen to contain two 
GAF (cGMP-specific phosphodiesterase, adenyl cyclase, FhlA transcriptional activator) 
domains25 in the N terminal region, whilst TbrC a FYVE26 domain ± not seen present in 
the other forms. The catalytic domain region, however, appears to be consistently located 
in the C-terminal of the polypeptide chain across all 4 PDE families. Interestingly, TbrB 
exists in two distinct, non-identical isoforms; TbrPDEB1 and TbrPDEB2, differing only in 
5 amino acid residues. Theoretically, both cAMP-specific enzyme isoforms would react in 
a very similar, almost identical way ± due to the variability of only one amino acid in the 
catalytic domain. According to a 2005 study by Laxman et al27, it is also suggested that the 
two GAF A domain present in both TbrB isoforms have a high affinity for both cAMP and 
cGMP.  
 
Understanding the existence of varying parasitic PDE types, their role as catalysts in cyclic 
nucleotide reaction pathways and in turn why that would make them drug targets of 
interest for the treatment of HAT is essential. However, understanding the biological 
function of the presented enzymes in the life cycle of the Trypanosoma brucei parasite is 
also vital for drug target validation. The chapter µTherapeutic Potential of 
3KRVSKRGLHVWHUDVH,QKLELWRUVLQ3DUDVLWLF'LVHDVHV¶ by Y. Shakur et al. in 
Phosphodiesterases as Drug Targets ± a 2011 book ± discusses the biological function of 
the varying parasitic PDEs28: 
 
It is reported that the characterisation and homozygous deletion of the cAMP-specific 
TbrPDEA enzyme shows very minor effects on cell growth due to a slight increase in 
cAMP concentration28. A 2001 study by Gong et al29 also states that despite being active, 
the deletion of TbrPDEA has no effect on cell proliferation, motility or morphology of 
bloodstream TrypomastigotesWKXVVXJJHVWLQJWKHJHQHWREHµQRQ-HVVHQWLDO¶LQWKHF$03
pathway previously shown in Figure 4. 
 
On the contrary, inhibition of the TbrPDEB isoforms appears to have a promising effect: A 
2002 article by R. Zoraghi and T. Seebeck30 reports that inhibition of the cAMP-specific 
TbrPDEB1 parasitic enzyme blocks the proliferation of bloodstream trypanosomes in 
vitro30. RNA interference experiments demonstrated that TbrB knock-out ± particularly the 
B1 isoform ± causes a drastic increase in intracellular cAMP concentration, reported to be 
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toxic for bloodstream trypanosome parasites. An article by H. de Koning et al31 further 
supports this claim; This article discusses the effects of known human PDE inhibitors on 
TbrPDEB1. Human and parasitic PDE enzymes are highly conserved31,32 due to having 
structurally very similar catalytic domains, hence in this study, a library of known and 
already explored human PDE inhibitors were screened against TbrPDEB1. A potent 
LQKLELWRUµ&SG$¶UHVXOWHGLQVXFFHVVIXOLQKLELWLRQRI7EU3'(%FDXVLQJDUDSLGF$03
concentration increase and eventual parasite death via cell lysis after 42 hours31 in vitro 
and also in vivo in mice models. These findings validate the pharmacological potential of 
TbrPDEB ± more particularly TbrPDEB1 ± as novel drug targets31. Furthermore, Figure 7 
and Figure 8 ± interpreted from a recent 2018 research paper by A. Blaazer et al33 ± 
GHPRQVWUDWHWKLVSKHQRPHQRQ,QWKLVVWXG\DV\QWKHVLVHGOLJDQGµ13'-¶ZDVXVHGWR
inhibit TbrPDEB1 in bloodstream form trypanosomes: 
As can be seen in Figure 7, there is a direct correlation between increasing NPD-008 

















Hence, the effect of high intracellular cAMP is depicted in Figure 833 on the following 
page: Healthy Tbr trypanosomes were incubated with NPD-DWȝ0 concentration in a 
cytokinesis assay. The parasites were examined after 0, 6, 12, and 24 hours of incubation 
(a-d)33. 
Figure 7: 
Effect of NPD-008 inhibitor on intracellular cAMP 
levels33 
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As can be seen, the parasite begins to degrade after 6 hours Figure 8(b). Large intracellular 
cAMP levels produced as a result of successful parasitic TbrPDEB1 inhibition in the case 
of T. brucei causes disrupted cell functionality as previously mentioned. The inability of 
successful cell division and cytokinetic defects33 prevents reproduction of parasitic cells, 
resulting in eventual parasite death, as seen in Figure 8(d). This equally confirms and 



















As previously mentioned, it is predicted that both TbrPDEB1 and TbrPDEB2 enzymes 
would behave in a similar way due to their almost identical catalytic domain. Due to this 
structural similarity, it is also suggested that both isoforms can functionally complement 
each other28,34,35. Therefore, it is hypothesised that strong dual-inhibition of both enzymatic 
isoforms would likely result in drastic cAMP increase and eventual parasitic death30. Note 
that it is apparent that enzyme inhibition does not alter DNA synthesis or nuclei 
division28,37. 
 
A 2012 study found that PDEC gene is inactive in some kinetoplastid species36. Despite 
successful biological and structural characterisation of PDEC in T. cruzi by H. Wang et 
al36, the study determines that this particular parasitic gene is not active, and hence not an 
Figure 8: 
Fluorescence microscopy of T. brucei incubated 
with ȝ0 NPD-008 inhibitor for: 0hr(a), 6hr(b), 
12hr(c) and 24hr(d) 
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essential enzyme in the parasite life cycle. Similarly, little is known about PDED other 
than the DNA sequence32. However, the validation of the TbrPDEB isoforms, more 
particularly TbrPDEB1 makes it a clear choice as a promising drug target for the treatment 
of HAT. The vast crystallographic knowledge existent for TbrPDEB1 over its B2 isoform 
counterpart make it an increasingly more appealing choice for research; Hence, the 
TbrPDEB1 enzyme is the key focus of this research project. The enzyme will be isolated 
and characterised appropriately, before undergoing fragment screening as a method of drug 
discovery.   
 
1.4 Fragment-based Screening (FBS) 
Fragment-based Screening (FBS) is a rapidly developing and widely used method as a 
modernized drug discovery approach. The principle of this technique relies on the 
screening of fragments ± small, low molecular weight compounds ± against a particular 
validated drug target38. Like High Throughput Screening (HTS)39, FBS aims to identify 
DFWLYHIUDJPHQWVDOVRNQRZQDVµKLWV¶± compounds which have a weak binding affinity to 
the chosen biological target (or the desired activity in a compound screen, as a broader 
term11). The identification of fragment hits to a drug target is a key starting point and the 
first step of novel drug design, as the understanding of fragment-target interactions and 
fragment hit optimization greatly aid in identifying promising lead compounds, as 
GHVFULEHGE\WKHµKLW-to-OHDG¶SULQFLSOH40. A 2011 article by JP Hughes et al. describes the 




Brief overview of a drug discovery process41 
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The article discusses the purpose of drug discovery programmes ± a disease or medical 
condition without suitable medical products available41 initiates a drug research 
programme and in turn target identification and validation. The drug discovery process 
may be summed up in a brief flow chart interpreted from the relevant 2011 study41, as seen 
in Figure 9 on the previous page. 
 
Following target validation, the importance and efficiency of hit discovery processes such 
as FBS comes to light. The ability to screen large libraries of small fragments directly 
against the drug target quickly gives rise to lead compounds which may be further 
optimized and expanded to suitable drug candidates. A brief summary of biophysical 








Large number of compounds 
Focused Previously identified hits of similar targets 
Fragment 




Use of crystal structures for molecule design 
Virtual 
Docking models through computational programs, hypothetic 
compound-target activity determination via a known crystal structure 





Soaking of compounds into protein targets of known NMR structures to 
determine interaction 
  
Aside from aiding in hit generation via screening techniques, NMR and X-ray 
crystallography also aid in validating hits by confirming binding interactions to the 
target42. These techniques are used alongside in vitro Biochemical assays43 in order to 
establish and measure ligand efficiency and the activity of each compound to the target 
Table 2: 
Brief overview of biophysical screening techniques41 
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through analytical techniques including dose-response curves41. As part of the optimization 
phase, modifications of lead compounds and active scaffolds by synthesizing similar 
chemotypical analogues aids in optimizing ligand efficiency by changing certain side 
chains or functional groups of said compounds and observing how the potency is affected. 
Docking models may also serve this purpose in the case of virtual screening. Screening and 
optimization techniques layered in different levels aids in bringing compound leads 
µcherry-picked¶ from a large fragment library to compounds that are DVµGUXJ-OLNH¶DV
possible; In other words, these compounds would possess44,45: 
 
x Potency towards the drug target (measured by Biochemical assays) 
x Desired physiological affect whilst interacting with the target 
x Solubility in water 
x Stable 
x Non-cytotoxicity  
x Selectivity versus other similar targets44,45 
 
Compounds possessing these properties would be optimal candidates for continued 
development by in vivo studies and eventual clinical trials. 
 
1.5 Aims 
Whilst TbrPDEB1 has been proven to be a valid drug target, the fact that the catalytic 
domain is soluble22 and amenable to crystallisation and Biophysical assay experiments is 
extremely advantageous and makes it an even more favourable target choice. A research 
paper published in 2017 by F. Svensson, A. Bender and D. Bailey22 reviews the use of FBS 
in identifying active PDE inhibitors. The paper reports a small selection of 6 fragment-
sized PDE inhibitors advanced to clinical trials, developed from a library consisting of 
thousands of fragments following screening and optimization techniques like those 
previously mentioned22.  
 
Hence in this project, a small set of 31 compounds put together by Dr. Fredrik Svensson 
from IOTA Pharmaceuticals46 ± a research company specialising in fragment-based drug 
discovery - will be used for several different screening methods against the validated 
TbrPDEB1 target enzyme. The small fragment library was put together by cross 
referencing commercially available compounds from vendor catalogues with compounds 
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possessing known human PDE activity as reported by ChEMBL47 ± a publicly available 
database which archives compounds and their bioactivity data against certain drug targets.  
 
The main tasks of this project are therefore to: 
x Transform gene expression host with TbrPDEB1 catalytic domain construct 
plasmid 
x Grow cells containing TbrPDEB1 plasmid construct 
x Induce TbrPDEB1 target protein production 
x Purify target TbrPDEB1 protein 
x Run a quality control by Proton 1D NMR on the purchased fragment library 
x Confirm PDE enzyme activity by Biochemical Assays 
x Screen fragment library against protein target by X-Ray Crystallography 
x Screen X-Ray Crystallography fragment hits against protein target by Biochemical 
assays  
x Screen X-Ray Crystallography fragment hits against protein target by NMR 
x Analysis of screening experiment hits, ranking ligands by potency / activity and 
µFKHUU\-SLFNLQJ¶IUDJPHQWVZLWKPXOWLSOHVFUHHQLQJFRQILUPDWLRQV 
x Hit-Lead follow up by performing a substructure similarity search on the 
determined best fragments in order to find chemotypically similar compounds to 
expand the parasitic PDE active fragment library 
 
Additionally, the overall aim of this project is to identify novel compounds as active 
TbrPDEB1 inhibitors through the use of several biochemical and biophysical techniques 












31 | P a g e  
 
2 Experimental 
2.1 Chemicals and Materials 
The chemicals, reagents and materials used in this research project were purchased from a 
number of different suppliers, listed as following: 
Bacterial growth media reagents such as Tryptone, Yeast Extract, Agar and Agarose were 
purchased from Melford Laboratories Ltd, in addition to HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), Tris (tris(hydroxymethyl)aminomethane) and IPTG 
LVRSURS\Oȕ-D-1-thiogalactopyranoside). Chloramphenicol and Kanamycin antibiotics, as 
well as buffer reagents such as Guanidine, Calcium Chloride, Zinc Chloride, Magnesium 
Chloride, PEG 3350 (polyethylene glycol), Sodium Formate, Imidazole, MES (4-
Morpholineethanesulfonic acid) and BME (2-Mercaptoethanol) were purchased from 
Sigma Aldrich. Other buffer reagents and general chemicals such as Sodium Chloride, 
DMSO (Dimethyl sulfoxide), SDS (Sodium dodecyl sulfate), 100% (v/v) Glycerol, Acetic 
acid, Absolute Ethanol, Hydrochloric acid, NuPAGE MOPS SDS running buffer (20x) and 
EDTA (Ethylenediaminetetraacetic acid) were purchased from ThermoFisher Scientific. 
Coomassie Brilliant Blue G-250 dye, as well as PageRuler Plus Prestained Protein SDS-
PAGE Ladder were both purchased from Bio-Rad and ThermoFisher Scientific, 
respectively. Premade NuPAGE 4-12% Bis-Tris Gels for electrophoresis were purchased 
IURP1RYH[ȝOȝODQGȝO;/*UDGXDWHG7LSVZHUHSXUFKDVHGIUom TipOne. 
Hampton 24-well plates and crystallography cover slips were purchased from Hampton 
Research.  
10 mg of 31 different compounds of varying chemotypes were purchased from Enamine, 
all of which were manually chosen due to their known binding affinity to human PDEs. 
These fragments can be seen listed below: (additional information can be found in 







































Various different screening experiments were performed using these ligands, as will be 
presented and discussed later in this report. Note that most of the experimental procedures 
found in this report were inspired by and adapted from several relevant research papers 
including a 2014 Fragment-based Screening report by A.R. Blaazer et al48, and a similar 
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2.2 TbrPDEB1 Catalytic Domain Construct 
The TbrPDEB1 catalytic domain plasmid construct was provided by the host laboratory at 
the University of Kent ligated in a pET28a bacterial expression vector. The plasmid map of 
this vector (generated by using the SnapGene software69), can be seen in Figure 10. Some 
key features of this construct include the KanR kanamycin resistance gene at base pairs 
560-1375 and the T7 promoter for bacteriophage T7 RNA polymerase, responsible for 
DNA transcription. The lac operator is repressed by the lacI repressor gene in order to 
inhibit the transcription in E. coli (Escherichia coli) cells. Upon addition of IPTG reagent, 
transcription is permitted as a result of the binding of IPTG and the lac repressor. The 
release of the repressor from the operon binding site allows T7 RNA polymerase to 
transcribe the DNA sequence. This transcription manipulation is beneficial as protein 
production can be induced whenever desired, allowing maximum cell growth prior to 
induction thus to increase yield as much as possible. Additionally, IPTG is not metabolized 
by E. coli cells and hence the rate of protein expression remains constant. The His6tag and 
thrombin site can also be seen at base pairs 5083-5127, serving the purpose of 
characterising the target TbrPDEB1 protein with a long histidine tail which is essential for 






















pET28a-TbrPDEB1 plasmid map, generated by SnapGene 
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2.3 Preparation and Transformation of Competent cells 
Note that all experiments involving bacteria handling were done using appropriate aseptic 
techniques e.g. in a sterile environment with the use of flames to kill bacteria and 
sterilizing all tools and media (by heating at 121 °C, pressure 1 bar in an autoclave) thus to 
reduce the likelihood of bacterial contamination. After each experiment, the workplace was 
cleaned using 70% ethanol and every container such as bottles and flasks were cleaned 
thoroughly using Virkon disinfectant. 
 
Making E. coli cells µFRPSHWHQW¶LVDFRPPRQWHFKQLTXHXVHGWRPDNH cells more likely to 
incorporate foreign DNA into their cytoplasm, thus allowing the manipulation of biological 
processes. There are several different ways of making E. coli cells competent; most 
commonly being by chemical or electroporation techniques. In this project, chemical 
methods were used to make E. coli cells competent. The BL21(DE3*) Codon-Plus Gram-
negative E. coli bacteria strain is an optimal host in this experiment for the expression of 
recombinant protein as the DE3 lysogen hosts the T7 RNA polymerase gene which 
controls the T7 promotor in the lac-operon mechanism essential for the translation process 
as previously mentioned, whilst also providing resistance to chloramphenicol, allowing the 
antibiotic to be used as a selection marker. The thin cell wall of this Gram-negative 
bacteria also allows for easier cell lysis.  
  
Hence, under sterile conditions, a sample of this E. coli strain (purchased from Agilent) 
was used to restreak an LB agar plate (10g tryptone, 5g yeast extract, 5g sodium chloride, 
15g agar per litre of dH2O, sterilised using an autoclave) along with 100ȝORI
chloramphenicol. The plate was incubated at 37 °C for 24 hours. A single colony was used 
to inoculate 20ml of LB media (10g tryptone, 5g yeast extract, 5g sodium chloride per litre 
of dH2O, sterilised using an autoclave) before the cells were left to incubate and grow to an 
optimal cell density of OD600 = 0.3, measured on a Spectrophotometer apparatus. A graph 


















The cells, maintained under cold conditions to prevent further cell growth, were 
centrifugated and resuspended with 0.1M calcium chloride before being aliquoted out 
ȝOLQPO(SSHQGRUIWXEHVDQGIUR]HQDW-80 °C. The purpose of aliquoting is to 
minimise freeze-thaw cycles which is known to reduce cell integrity. The calcium chloride 
treatment is key to chemically create cell competence, as the calcium ions increase cell 
wall permeability allowing for uptake of foreign DNA. 
 
The following step is the genetic alteration, or transformation of the cells by introducing 
foreign DNA into the system. As previously stated, the catalytic domain of the TbrPDEB1 
enzyme between residues 668 and 905, shown in Figure 12, was isolated and ligated into a 










1ȝORIWKLVSODVPLG construct was added to an ȝODOLTXRWRIBL21(DE3*) Codon-Plus 






















Graph depicting BL21(DE3*) Codon-Plus competent cell growth  
Figure 12: 
TbrPDEB1 catalytic domain used for transformation 
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medium (2g tryptone, 0.5g yeast extract, 1M sodium chloride, 1M potassium chloride, 2M 
Mg2+ and 20% glucose, per 100ml of H2O, sterilised using an autoclave) was added to the 
cells before they were left to incubate at 37 °C for 30 minutes to recover from the heat 
shock. The purpose of this heat shock is to alter the fluidity of the cell membrane, which is 
now permeable due to the cell being competent, by creating pores. These pores, created by 
the sudden increase in temperature, allow the pET-28a-TbrPDEB1 plasmid construct to 
pass through the pores and enter the cell. The pores once again close upon temperature 
decrease, thus to keep the foreign DNA within the cell, and prevent any other DNA from 
entering. The cells were then spread on a LB agar plate with 100mM chloramphenicol and 
kanamycin antibiotics, as the newly transformed cells have chloramphenicol resistance 
from the original E. coli strain, and kanamycin resistance from the original plasmid 
construct. The plate was left to incubate at 37 °C for 24 hours. A second plate was left to 
grow alongside as a control, with no plasmid added, hence no kanamycin resistance gene 
being present in the cells. As expected, there was no bacterial growth on the control plate 
as the cells were killed by the kanamycin antibiotic, whilst on the experimental plate 
colonies grew healthily indicating successful uptake and expression of the introduced 
recombinant genetic material. 
 
2.4 Cell Growth and Expression of Target Protein 
A single colony was picked out from the plate and used to inoculate a 250ml Erlenmeyer 
flask containing 50ml sterile LB media and 50ȝO of 100mM chloramphenicol and 
kanamycin antibiotics. This starter culture was left to grow overnight for a further 24 
hours, incubated at 37 °C and 200rpm (rotations per minute). 25ml of starter culture was 
used to inoculate 2L of sterile 2YT media (16g tryptone, 10g yeast extract, 5g sodium 
chloride per litre of dH2O, sterilised using an autoclave), in 2 x 2.5L flasks with the 
addition of 1ml of chloramphenicol and kanamycin antibiotics. The purpose of antibiotic 
addition is to maintain the function of the new genetic material by expressing the 
respective genes; in this case being antibiotic resistance, as without gene expression 
protein production cannot be induced. Hence, the cells were left to grow in sterile 2YT 
media at 37 °C up to an optimal OD600 reading of 0.6-0.8 as seen in a similar experiment in 
$5%OD]HHU¶Vet al 2015 paper48. An OD600 reading was taken hourly using a 
Spectrophotometer apparatus, thus to keep track of the rate of cell division. Note that a 
reference sample was taken from one flask directly prior to inoculation. The data recorded 
can be seen tabulated in Table 3 on the following page. 
 










Flask 2 was left to incubate for a further 10 minutes, reaching an ideal OD600 value of 
0.818.  
 
Having reached optimal cell density, the flasks were left in a cold room at 4 °C for 20 
minutes to prevent further cell division. Protein production was induced with the addition 
of 300mM IPTG, initiating transcription and translation of protein as previously discussed. 
The flasks were left to incubate at 18 °C for 48 hours, maximizing protein production.  
The TbrPDEB1 protein-containing cells were collected 48 hours later and harvested via 
centrifugation at 5000rpm IRUPLQXWHV7KHFHOOVIRUPDFOXVWHURUDµSHOOHW¶DWWKH
bottom of each flask due to the strong centripetal force created by the rapid spinning. The 
collected pellets weigh a total of 21.40g of protein-containing cells from a total of 2L of 
media. Note that from this stage, all work was done under cold conditions, either with ice 
or by setting any machinery used to 4 °C, thus to prevent denaturing or disturbing the 
protein. 
The cell pellets were then resuspended and diluted in lysis buffer (10ml of buffer per gram 
of cells), which consists of:  
 
Lysis buffer ± 
x 20mM Tris-HCl pH 7.5 
x 200mM Sodium Chloride 
x  10mM Imidazole 
x 5% Glycerol 
x 2mM BME 
x 2 Protease Inhibitor Tablets 
 
The resuspended cells were then lysed by a French press cell disruptor under 20,000 KPSI 
(kilo pounds per square inch) in order to release the TbrPDEB1 protein in the cells into a 




0 0 0 
1 0.172 0.151 
1 ½ 0.354 0.314 
2 0.675 0.597 
Table 3: 
Transformed competent cell growth 
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suitable environment of the lysis buffer. The cell lysis solution was once again 
centrifugated at 17,000rpm for 30 minutes in order to separate the unwanted cell debris and 
the desired, TbrPDEB1 protein-containing supernatant.  
 
2.5 Purification of Target Protein 
The desired target protein acquired is contaminated with other unwanted proteins produced 
during the expression process. The following step is to separate the desired protein from 
the lysate mixture by means of several different chromatographic techniques. A Fast 
Performance Liquid Chromatography (FPLC) pumping mechanism is used to control the 
rate at which the mobile phase (in this case the cell lysate) passes through the stationary 
phase. The stationary phase varies depending on the separation technique. The machinery 
detects separation of proteins by using an ultraviolet detector, as proteins absorb UV light 
at 280nm mostly due to the aromatic rings present in amino acid residues. This data can be 
tracked and analysed using AKTA70 ± a liquid chromatography software. The purification 
stage was split up in a number of different techniques: 
 
2.5.1 Immobilized Metal Affinity Chromatography (IMAC) 
The principle of IMAC works by using the terminal histidine base pairs on the original 
vector as previously mentioned; Histidine has a high binding affinity to and is able to form 
a chelate-metal complex with several types of immobilized metal ions including nickel, 
cobalt, and copper under specific buffers. Following protein expression, the base pairs 
shown are translated to a chain of 6 His-tags attached to the desired TbrPDEB1 protein. 
Therefore, the protein lysate can be passed through a column packed with a Chelating 
Sepharose resin stationary phase charged with Ni2+ ions, which will selectively retain any 
proteins containing this histidine tag, thus isolating desired protein within the Nickel 
column. The column can then be washed several times with buffer, separating out 
undesired protein still remaining in the column, before the desired protein can be eluted out 
by washing through with imidazole ± which has a greater binding affinity to Nickel than 
histidine, and will therefore displace the bound protein from the column, allowing for 
collection. Following elution, the collected protein is passed through an additional larger 
column for the purpose of desalting the solution by separating out the imidazole from the 
protein by size exclusion, as the larger salt molecules pass through the tightly packed resin 
beads of the desalting column much slower than the protein. Instead, the protein is buffer 
exchanged with desalting buffer. This step is required as the presence of imidazole in a 
protein solution for long periods of time can cause the stripping of divalent metal ions 
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present in proteins to occur, which in turn would cause the protein to lose activity. This 
will be discussed in greater detail later in this report. 
 
Hence, three different buffers were made up ±  
Buffer A (Binding buffer) ± 
x 20mM Tris-HCl pH 8 
x 200mM Sodium Chloride 
x 20mM Imidazole 
x 5% Glycerol 
x 2mM BME 
 
Buffer B (Eluting buffer) ± 
x 20mM Tris-HCl pH 8 
x 200mM Sodium Chloride 
x 1M Imidazole 
x 5% Glycerol 
x 2mM BME 
 
Buffer C (Desalting buffer) ±  
x 50mM Tris-HCl pH 8 
x 100mM Sodium Chloride 
x 5% Glycerol 
 
Note that in every purification experiment, buffers were made up in cold bottles, as the pH 
of Tris-HCl is known to be temperature dependant, and as the experiment is done in the 
FPLC machinery at 4 °C, bottles were pre-chilled thus to ensure pH remained constant. 
Additionally, all solutions used were filtered and degassed accordingly to remove any air 
and small particles in order to prevent blockage of the FPLC pumps. Pumps A and B on 
the machinery were initially washed with deionised H2O and equilibrated in buffers A and 
B, respectively. 
 
A 5ml HisTrapTM HP column prepacked with charged Ni2+ Sepharose beads was connected 
to the FPLC and washed with 10 column volumes (C.V.) of deionised H2O (50ml), and 
equilibrated with 10 C.V. of Buffer A. Similarly, a 54ml HiPrepTM desalting column 
prepacked with Sephadex G-25 Fine, cross-linked dextran resin was washed with 2 column 
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volumes of deionised H2O (108ml) and equilibrated with 2 C.V. of desalting buffer. The 
cell lysate was loaded into the Nickel column through pump A, before contaminants were 
separated out by washing the column with a further 10 C.V. of Buffer A. The wash through 
and the flow through were collected. The his-tagged protein bound to the Nickel column 
was then eluted with an increasing imidazole concentration (using Buffer B) at a linear 
gradient and collected in fractions. Fractions yielding a large UV peak on the AKTA 
software (as can be seen in the Results and Discussion section) indicating protein elution 
were sampled and used for an SDS-PAGE experiment in order to visually evaluate the 
purity and basic characteristics of the yielded protein following the first purification step 
by inspection of a polyacrylamide gel. The appropriate fractions were combined and 
passed through a desalt column equilibrated in Buffer C as described previously in order to 
remove imidazole and buffer exchange the yielded protein. The protein concentration was 
also measured using a Spectrophotometer apparatus.  
 
2.5.1.1 SDS-PAGE 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, or SDS-PAGE is an analytical 
method used in biochemistry with the principle of separating charged molecules in an 
electric field based on their molecular weight, or size. SDS is a detergent that denatures 
and unfolds protein structures into its original subunits by binding to the polypeptide 
chains to form complexes with a constant charge to mass ratio which negatively charges 
SURWHLQV+HQFHȝOVDPSOHVRIWKHORDGHGO\VDWHIORZWKURXJKZDVh through, and eluted 
protein fractions ZHUHWDNHQDQGPL[HGZLWKȝORI2x SDS Sample Buffer, consisting of: 
 
SDS Sample Buffer (2x) ± 
x 10mM Tris-HCl pH 6.8 
x 4% (w/v) SDS (sodium dodecyl sulfate; electrophoresis grade) 
x 0.2% (w/v) Bromophenol blue 
x 20% (v/v) Glycerol 
x 200mM DTT (Dithiothreitol) 
 
The mixed samples were then heated to 150 °C on a heat block to further denature the 
SURWHLQE\UHGXFLQJGLVXOSKLGHERQGVȝORIHDFKKHDWHGPL[WXUHDQGȝOof a Precision 
Plus Protein Dual Colour standard are pipetted into the wells of a gel cassette. An electric 
current is applied across the gel, which is immersed in NuPAGE MOPS SDS Running 
Buffer (1x), causing proteins with a negative charge to migrate towards the positive anode 
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at the bottom of the cassette. The rate at which a certain protein travels across the gel is 
determined by its size ± smaller proteins being able to pass through the pores of the gel 
matrix at a faster rate are expected to appear more towards the base of the cassette, and 
vice versa. This way, every protein in the samples taken can be analysed on the gel by their 
molecular weight, which can be determined by comparing to the known standard also 
applied. Hence, the desired TbrPDEB1 protein with a calculated molecular weight of 40.57 
kDa (kilodaltons) can be seen in the Results and Discussion section. 
 
2.5.2 Secondary IMAC 
The protein sample is seen to contain additional contaminants, hence further purification 
steps are required. Prior to the next purification step, the protein sample was diluted with a 
further 50ml of desalting buffer to prevent protein aggregation and eventual crashing. 75ȝO 
of Thrombin protease enzyme (2 units/microlitre) was added to the sample (determined by 
adding 10 units of enzyme per mg of protein) in order to cleave the histidine tag present on 
the desired protein, before being left at 4 °C for 24 hours. The columns used were cleaned 
accordingly. 
 
A small, table-top 5ml column with a sieve and Chelating Sepharose Fast Flow resin was 
charged with 2.5ml of a 0.1M solution of NiSO4, pH 6. The column was prepared 
appropriately for a manual IMAC experiment, adapted from the example previously 
discussed. The protein sample was loaded into the column, which was equilibrated in 10 
C.V. of desalt buffer (20ml). Assuming successful thrombin his-tag cleavage, the desired, 
untagged TbrPDEB1 protein can be collected in the flow through. Any remaining untagged 
protein is washed through with an additional 10 C.V. of desalt buffer, leaving any 
contaminants with remaining histidine tags bound to the Nickel column. Note that the flow 
through and the wash through, assumed to contain desired protein, are combined. The 
remaining his-tagged contaminants are eluted with 10 C.V. of desalting buffer containing 
300mM imidazole. SDS-PAGE samples were taken after each step, in order to observe 
cleavage quality. The column used was cleaned accordingly. The combined wash and flow 
solution was diluted with 100ml of desalt buffer and was prepared for the next purification 
step. 
 
2.5.3 Ion Exchange Chromatography (IEX) 
The method to IEX-Q, or Ion Exchange Chromatography-Quaternary Ammonium is 
similar to the IMAC procedure; however instead of separation by metal-chelate affinity, 
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separation is based on charge difference. The principle behind this method works by 
exploiting the charge difference between different molecules or proteins in a sample. A 
desired protein or molecule in a sample can ionically bind to an oppositely charged 
stationary phase; Similarly charged contaminants are repelled by the stationary phase, or 
contaminants with varying charges bind very weakly and hence elute much easier ± in any 
case, separation occurs, once again isolating the desired protein from any remaining 
impurities. In order for a target protein to bind to the stationary phase, its isoelectric point 
(pI) (the point at which the protein carries a net zero charge) has to be determined. Once 
this is known, the pH of the buffers and hence charge of the stationary phase can be 
manipulated to give ideal ionic binding to the desired protein.  
The isoelectric point of a protein is determined by working out the isoelectric point of 
every amino acid in the protein structure and taking the average. In turn, the pI of amino 
acids can be calculated by averaging the total pKa of all the functional groups in the 
residue ± giving a value of pH at which the respective amino acid is zwitterionic.   
Using the amino acid sequence of the TbrPDEB1 protein, the pI is calculated to be 5.15 
using a protein isoelectric point calculator (IPC)85. Therefore, by increasing the pH past the 
pI, the protein becomes less protonated due to increasing OH- ion concentration as seen in 
simple Lewis acid-base reactions, making the protein much more prone to ionically bind to 
a positive cationic stationary phase; in this case, the positively charged quaternary 
ammonium, NH4+. 
Hence, two different buffers are made up ± 
 
IEX-A (QA buffer) ±  
x 20mM Tris HCl pH 8 
x 100mM Sodium Chloride 
x 5% Glycerol 
x 1mM BME 
 
IEX-B (QB buffer) ± 
x 20mM Tris HCl pH 8 
x 1M Sodium Chloride 
x 5% Glycerol 
x 1mM BME 
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Pumps A and B of the FPLC machinery were equilibrated in buffers QA and QB, 
respectively. A 5ml HiTrapTM Q HP column prepacked with Sepharose beads was washed 
with 10 C.V. of deionised H2O, before being equilibrated with 10 C.V. of QA buffer. The 
protein sample was loaded into the column through pump A. The flow through was 
collected and sampled for an SDS-PAGE. Any weakly bound contaminants are washed 
through with an additional 10 C.V. of QA buffer. The desired protein, assumed to remain 
bound to the stationary phase, is eluted out by an increasing salt concentration (with QB 
buffer) at a linear gradient. Elution fractions were collected as described in the IMAC 
purification step. The increasing salt concentration causes bound proteins to desorb from 
the stationary phase. The rate of protein desorption is dependent on ionic interaction 
strength between the protein and the stationary phase. In terms of the desired protein, if pH 
is too low, causing the protein to be closer to net zero charge, the ionic interaction would 
be very weak and displacement would easily occur (thus failing to separate from protein 
contaminants). Having a low pH also risks protein aggregation and crashing. On the 
contrary, if pH is too high, it would be difficult to displace bound protein from the column, 
even at high salt concentrations. Hence, an optimal pH of 2 above the pI is used. The 
recorded AKTA graph can be seen in the Results and Discussion section. SDS-PAGE 
samples were taken from the appropriate fractions. The TbrPDEB1 protein containing 
fractions ± as determined by the SDS-PAGE experiment ± were combined. The 
concentration and yield were recorded. The next purification step, Size Exclusion 
Chromatography, was not required as the protein has reached ideal purity, indicated by no 
contamination bands being present on the SDS-PAGE gel (as can be seen on the IEX SDS-
PAGE gel in the Results and Discussion section). 
 
The combined fraction contents were buffer exchanged with Storage Buffer and 
concentrated using an Amicon Ultra-N&HQWULIXJDO)LOWHU'HYLFHRUDµFRQFHQWUDWRU¶ 
 
Storage Buffer consists of: 
x 20mM Tris HCl pH 7.5 
x 5% Glycerol 
x 50mM Sodium Chloride 
x 2mM BME 
x 1mM MgCl2 (Magnesium Chloride) 
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Once the QB buffer was removed, the concentrator was topped up with Storage Buffer and 
spun again. The protein precipitant was discarded. The protein sample was separated in 
ȝODOLTXRWVDQGFU\RJHQLFDOO\IUR]HQDW-80 °C. The concentration was measured using a 
Spectrophotometer apparatus, using an extinction coefficient of 24,420 and molecular 
weight of 40.57 kDa as characteristics for the TbrPDEB1 protein.  
 
2.6 Biochemical Assays of Target Protein 
Note that following purification of the target protein, the 31 solid 10mg compounds 
purchased were used to prepare 100mM and 400mM compound super stocks in 100% 
DMSO which were used for several experiments as will be later discussed. 
A Lonza PDELight HTS cAMP phosphodiesterase kit50 was used to perform several 
experimental assays in order to: 
 
x Confirm TbrPDEB1 enzyme activity 
x Optimise concentrations of experimental reagents 
x Assess inhibition of purchased compounds against TbrPDEB1 
x Determine the Km of the purified enzymatic TbrPDEB1 protein 
x Produce Dose-Response curves of active compounds against TbrPDEB1 
 
This bioluminescent detection assay works by exploiting the previously discussed reaction 
pathway in Figure 4. Assuming a working PDE, the amount of AMP converted from 
cAMP as a result of a hydrolysis reaction catalysed by PDE enzyme can be indirectly 




As can be seen, the AMP detection reagent used in this assay kit converts AMP to ATP 
(adenosine triphosphate). The luciferase also present in the kit is involved in the production 
of light over time from ATP, luciferin and free oxygen, as can be seen in the reaction 
scheme in Figure 13. The light emitted can be measured by a FLUOstar Omega 
             PDE              AMP-DR                                                Luciferase 
cAMP  Æ  AMP  Æ  ATP + Luciferin + O2 Æ Oxyluciferin + AMP +       
. 
                                                                            PPi + CO2 + LIGHT 
Figure 13: 
Lonza PDELight assay kit reaction scheme 
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Luminescence plate reader (from BMG LABTECH) and is directly proportional to the 
quantity of AMP broken down from cAMP. Hence, this is beneficial for PDE activity 
studies.  
 
2.6.1 Verifying TbrPDEB1 activity and determining working 
concentrations 
Note that this protocol was adapted from the official Lonza PDELight protocol50 as will be 
discussed further in greater detail. 
20ȝO of TbrPDEB1 protein at a concentration of 1mg/ml was used to prepare a 200ȝO serial 
dilution as follows: 1:100, 1:300, 1:500 and 1:1000, 1:10,000 with Stimulation Buffer, 
consisting of: 
 
x 50mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) pH 7.8 
x 100mM NaCl 
x 5mM MgCl2 
x 0.1mM ZnCl2 (Zinc Chloride) 
x 5% Glycerol 
 
10ȝM aliquots of cAMP and AMP were also prepared and diluted with Stimulation Buffer. 
80% Detection Reagent (diluted with Reconstitution Buffer) was also prepared.  
17.5ȝO of each PDE dilution was pipetted into a white Corning 96-well assay microplate, 
followed by the addition of 17.5ȝO of Stimulation Buffer consisting of 6% DMSO 
(dimethyl sulfoxide). This was repeated 3 times for each dilution (in triplets). The plate 
was covered and incubated at room temperature for 20 minutes following this step. Also 
note that the plate was spun for several seconds after each step, in order to mix the added 
reagents and prevent protein aggregation. 35ȝO of detection reagent was then added, 
followed by 35ȝO of cAMP. In addition to the triplets of dilutions, positive and negative 
controls were also ran simultaneously in triplets. 35ȝO of AMP was directly added to the 
positive control instead of cAMP, whilst for the negative control the 17.5ȝO of TbrPDEB1 
was replaced with 17.5ȝO of Stimulation Buffer. The plate was read as previously described 
for a duration of 55 minutes.  
 
A similar assay was also performed with a constant optimal TbrPDEB1 concentration and 
a similar serial dilution of cAMP, thus to determine enzyme kinetics by working out the 
Km through a Michaelis-Menten graph. These graphs are seen plotted in the Results and 
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Discussion section. A variation of this protocol was also used to run the fragment screen 
following determination of a suitable TbrPDEB1 concentration, with the addition of 17.5ȝl 
of fragment in solution at a concentration of 200ȝM (made by dilution of a 100mM super 
stock with Stimulation Buffer). The plate was once again read for 55 minutes, and a 
suitable graph was plotted, as will be later discussed in the Results and Discussion section.   
 
2.7 X-Ray Crystallography 
A crystallisation protocol was adapted from a relevant 2013 study by C. Jansen et al49. As 
a brief overview, X-ray Crystallography work was conducted in two parts:  
The first being crystallisation via XCHEM ± a semi-automatic lead Fragment-based 
discovery approach, allowing the user to quickly set up nanolitre crystallisation drop plates 
and rapidly screen fragment libraries consisting of large numbers of varying ligand 
chemotypes using advanced machinery at the Diamond Light Source78 in Oxfordshire; 
further details will be discussed later on in this report.  
The second part being manual crystallisation ± which included manually setting up crystal 
drops and crystal soaks at the University of Kent, a much slower and time demanding 
method, however more suitable for this project considering that the fragment library only 
consists of 31 ligands.  
Nevertheless, despite using two varying crystallisation techniques, both methods use the 
same crystal soaking principle: 
 
The aim of a crystal soaking experiment is to make highly concentrated super-stock 
VROXWLRQVRIHDFKFRPSRXQGDQGXVHWKHPWRµVRDN¶FU\VWDOOLVHG7EUPDEB1 protein. Crystal 
soaking is a technique where yielded crystals are introduced to an environment containing 
the original crystallisation conditions in solution with a concentration of a given compound 
± dissolved in DMSO. In theory, the compound would be taken up by the PDE target as a 
result of the soak, depending on the binding affinity. The duration of the soak, 
concentration of compound and quality of crystal should all be considered ± the longer the 
soak duration or the higher the soak concentration ± the more likely it is that the compound 
is taken up by the PDE target. However, long exposures and high concentrations of DMSO 
can damage the crystal lattice and yield poor crystallographic data or completely shatter 
the crystal altogether. Therefore, a range of variables were tested to aid in optimising the 
conditions most suitable to the yielded crystals. 
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Following soaking, the compound containing crystals underwent X-Ray diffraction at the 
Diamond Light Source thus to yield crystallographic data and diffraction patterns which 
were used to visualise the structure three-dimensionally with the use of softwares such as 
CCP4i266 and COOT67. 
 
2.7.1 Crystallisation by XCHEM 
$ȝODOLTXRWRISXULILHGSURWHLQLQ6WRUDJH%XIIHUZDVEXIIHUH[FKDQJHGWR
Crystallisation Buffer, made up of: 
 
x 20mM Tris HCl pH 7.5 
x 5% Glycerol 
x 2mM BME 
 
The buffer exchanged protein was centrifugated down to a concentration between 7-
7.5mg/ml, interpreted from a similar study by C. Jansen et al49 as an optimal concentration 
for crystallisation, however it was found that crystals would form even at concentrations as 
low as 6mg/ml. The crystallisation conditions were made up as following: 
 
x 100mM MES (2-(N-morpholino) ethane sulfonic acid pH 6.5 
x 18% PEG (polyethylene glycol) 3350  
x 400mM Sodium Formate 
x 300mM Guanidine 
 
ȝORIFU\VWDOOLVDWLRQFRQGLWLRQVZHUHSLSHWWHGLQWRHDFKZHOORID-well 3-drop SwissCI 
dispensing plate purchased from Molecular Dimensions. 0.2ȝOȝOGURSVRISURWHLQ
were laid down on the wells of the dispensing plate using a Mosquito, allowing vapour 
diffusion crystallisation to occur via a sitting drop technique. This quickly super saturates 
the protein drops, yielding TbrPDEB1 crystals at 4 °C within 48 hours.  
 
The crystal plate was analysed using a Formulatrix imager at the Diamond Light Source in 
order to select the best crystals and filter out poor drops. The wells containing the best 
crystals were selected and soaked with a similar dispensing plate containing the entire 
fragment library at a 100mM concentration, using an ECHO 555 dispenser ± a precise 
nanolitre volume Liquid Handler. Soaks were done for 3 hours, with 20mM and 30mM 
compound concentrations. The soaked crystals were then mounted on loops using the aid 
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of a Shifter, before being hit with X-Ray beams. The crystallographic data was acquired 
from various different auto-processing pipelines such as fast-dp and autoPROC. An 





2.7.2 Manual Crystallisation  
Manual crystallisation was set up in a similar way, with the exception of a 24-well Linbro 
SODWHEHLQJXVHGȝORIFU\VWDOOLVDWLRQFRQGLWLRQVZHUHSLSHWWHGLQWRDOOZHOOVRIWKH
GLVSHQVLQJSODWHȝOSURWHLQȝOFU\VWDOOLVDWLRQFRQdition drops were combined on a 
circular glass slide, which was placed upside down on each well on the plate, creating a 
similar vapour diffusion with a hanging drop technique. This technique also yielded 
TbrPDEB1 crystals at 4 °C within 48 hours. 
Figure 14: 
XCHEM platform workflow A.K. Singh 2017 
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400mM compound super stocks were used to prepare compound soak solutions of varying 
concentrationsȝOGURSVRIFRPSRXQGVROXWLRQVZHUHODLGRXWRQ circular glass slides, 
which would later be placed on a fresh dispensing plate as previously described. 
TbrPDE%FU\VWDOVZHUHPDQXDOO\µILVKHG¶RXWRIWKHRULJLQDOGURSVXVLQJ circular 100-
250-micron loops under a microscope and placed into the compound solution drops to 
allow soaking. Multiple crystals were placed in each drop to increase the chance of crystal 
survival whilst also varying soak time. Following soaking, the crystals were once again 
manually fished out and were briefly placed in a drop of Cryogenic Solution, containing 
80% crystallisation conditions and 20% glycerol. The crystals were then archived in a puck 
which was kept immersed in liquid nitrogen at all times. The pucks were stored in a 
transportation Dewar decanted of liquid nitrogen and shipped to the Diamond Light Source 
to yield crystallographic data by undergoing X-Ray diffraction as previously described. 
 
2.8 Nuclear Magnetic Resonance (NMR) 
NMR experiments were conducted in a 600MHz Avance III spectrometer with Cryoprobe 
throughout this research project to analyse and verify the purity of the purchased 
compounds whilst also using more complex sophisticated NMR experiments to analyse the 
TbrPDEB1 protein itself and observe binding affinity to compounds of interest determined 
by X-Ray Crystallography. $OO105GDWDZDVDQDO\VHGDQGLQWHUDFWHGZLWKXVLQJ%UXNHU¶V
Topspin 3.5pl7 NMR processing software71. 
 
2.8.1 Compound Quality Control (QC) 
100mM compound super stocks were used to make 1mM fragment solutions made up to 
ȝORI'062LQDPP105WXEH. Proton 1D experiments were ran on all 31 
fragments. The yielding spectra were analysed accordingly, identifying any impurities 
present. The tubes were cleaned appropriately.  
 
2.8.2 Protein NMR 
$ȝODOLTXRWRISXULILHGSURWHLQLQ6WRUDJH%XIIHUZDVFRQFHQWUDWed down to 3mg/ml 
and buffer exchanged to Phosphate Buffer, made up of 100mM Sodium Chloride and 
20mM phosphate pH 7.57KHSURWHLQLQ3KRVSKDWH%XIIHUVROXWLRQZDVPDGHXSWRȝO
in a 3mm NMR tube, which was spiked with 5% D2O. A 1D Proton NMR experiment 
yielded a 1H spectrum for the TbrPDEB1 protein, as can be seen later in this report. 
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2.8.3 Protein-Ligand Binding Affinity NMR 
Compounds that gave the best crystallography results were brought forward for 
biophysical screening experiments to test for binding affinity. Two 3mm NMR tubes were 
made up as follows (for each compound tested): 
 
Tube 1 ± 0.5mM Ligand, 0.01mM Protein in 25ȝORI3KRVSKDWH%XIIHUVSLNHGZLWK
D2O 
 
Tube 2 ± P0/LJDQGLQȝORI3KRVSKDWH%XIIHUVSLNHGZLWK'2O 
 
The above tubes were used for STD (Saturation-Transfer Difference), CPMG (Carr-
Purcell-Meiboom-Gill) and WaterLOGSY (Water-Ligand Observed via Gradient 
Spectroscopy) NMR experiments to test for binding affinity. 
 
2.8.3.1 STD NMR 
1H STD experiments were acquired on a Bruker Avance III 600 MHz spectrometer at 
25°C, using 16,384 points over a spectral width of 9615 Hz. A total number of 256 scans 
were acquired with an acquisition time of 0.85 seconds. Saturation was achieved using 
EBURP284 pulses over a 50ms saturation period; Saturation was applied at -0.3 / -30ppm 
for the on and off resonance experiments respectively. Water suppression was achieved 
using excitation sculpting81 and the spectra was referenced against water. Data were zero 
filled and Fourier transformed using topspin 3.5p7. A convolution filter82 was used to 
further suppress water the residual water signal (sfil, bcfw 0.2ppm) and an exponential line 
broadening of 3 Hz was applied and the spectrum was referenced against water74,75. 
 
2.8.3.2 waterLOGSY NMR 
1H WaterLOGSY73 experiments were acquired on a Bruker Avance III 600 Hz 
spectrometer at 25°C, with 32,768 points (spectral width 9615 Hz) with a total number of 
256 scans measured within an acquisition time of 1.70 seconds. Data was processed 
using topspin 3.5pl7 and line broadening of 3.0 Hz was applied. Acquired data was 
processed in topspin 3.5pl7. A convolution filter82 was used to further suppress residual 
water signals (sfil, bcfw 0.2ppm) with an exponential line broadening of 3.0 Hz. The 
spectrum was referenced against water. Water inversion was achieved using a 6.4ms 
eSNOB inversion pulse. The NOE mixing period was 1.2s during which a lower power of 
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10G/cm Z gradient pulse was applied. Further suppression of the protein signals was 
achieved using 20 cycles of a CPMG sequence with an inter-pulse delay of 1ms. 
 
2.8.3.3 CPMG NMR 
1H CPMG77 experiments were acquired on a Bruker Avance III 600 Hz spectrometer at 
25°C. Data was collected with 16,384 points and a spectral width of 9615 Hz, with 
a total number of 128 scans and an acquisition time of 0.85s. The CPMG element used 
600 cycles with a delay of 1ms between 180-degree pulses. Water suppression was 
achieved using a 3:9:19 Watergate sequence83 and 100ms of pre-saturation. Acquired data 
was processed in topspin 3.5pl7, a convolution filter82 was used to further suppress residual 
water signals (sfil, bcfw 0.2ppm) with an exponential line broadening of 3.0 Hz and the 
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3 Results and Discussion 
3.1 Mass Spectrometry 
A mass spectrometry experiment was performed on a 25ȝM sample of purified TbrPDEB1 
protein following purification thus to ensure the 40.57kDa protein mass. This can be seen 




As can be seen, the deconvoluted mass spectrum shows a large abundant peak of x105 
intensity at mass 40573.5Da, the correct mass for the TbrPDEB1 protein target. 
Additionally, a smaller peak is seen at 40647.9Da. The 74.4Da mass difference between 
the two peaks is due to a mass 74.4Da glycerol peak being present and detected in the 
sample due to remaining in the protein sample following storage buffer exchange. Thus, 













TbrPDEB1 deconvoluted mass spectrum 
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3.2 Purification Analysis 
This chapter is dedicated to discussing the results of the protein purification methods to 
further characterise the TbrPDEB1 protein and present the yield. 
 
3.2.1 IMAC AKTA Graph 




The IMAC purification process can be split up into three stages: Load, Wash, and Elution. 
The load and wash stages of the protein sample can be seen plotted on a graph in Figure 16 
above. As depicted, the ultraviolet detector reading is seen to spike directly after loading, 
quickly reaching the detection limit. The reason for this is due to the large quantity of 
protein present within the cell lysate mixture acquired after protein expression and 
induction ± consisting of desired protein, but mainly contamination. After loading the 
400ml of lysate mixture, the UV reading is seen to quickly decline as a result of the wash 
stage. Once the lysate has passed the detector and is fully loaded into the column, a further 
10 C.V. of binding buffer is pumped through the system as previously discussed in order to 
wash any remaining weakly-bound protein contaminants out of the column. This stage 
continues until the UV reading plateaus as seen at 420ml, indicating binding buffer with no 
protein present and hence a successful wash, leaving the desired histidine-tagged protein 






















TbrPDEB1 IMAC Sample Load and Wash graph 





The protein is eluted with an increasing imidazole concentration at a linear gradient, shown 
in green in Figure 17. The increasing imidazole concentration displaces the bound 
histidine-tagged protein as indicated by the large UV peak seen at 22ml. The elution 
samples were collected in 5ml fractions until everything in the column was displaced, 
guaranteed by a 100% (1M) imidazole concentration. The UV is seen to continue to 
increase gradually in parallel with the gradient concentration; This however is not due to 
any protein elution; On the contrary, imidazole also has an ultraviolet absorbance at 
280nm, explaining the linear UV trend. For a similar reason, concentration measurements 
at this stage are not accurate due to the imidazole present in the sample which is likely to 
give incorrect readings. Fractions 5, 6, 8, 9, 13 and 19 were collected and sampled to be 




TbrPDEB1 IMAC Elution and Fractionation graph 




























UV Gradient Concentration Fractions
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3.2.2 IMAC SDS-PAGE Gel 
An interpreted image of the SDS-PAGE Gel following IMAC purification  
can be seen in Figure 18. The PageRuler Plus Prestained Protein Ladder can also be seen 
in Figure 1951.  The columns are labelled as follows (from left to right): 
ladder, supernatant, flow through, wash through, Fraction 5, Fraction 6, Fraction 8, 






As expected, the supernatant and flow through samples yielded a large number of thick 
bands on the gel due to a large quantity of contaminant protein being present. The 
TbrPDEB1 protein of interest is seen present in Fractions 6 and 8, indicated by thick bands 
at 40kDa (as seen circled), deduced by comparing to the adjacent protein ladder figure. 
This is the expected position of TbrPDEB1 protein on the gel as the determined molecular 
weight by Mass Spectroscopy was measured to be 40.57kDa. This implies successful gene 
expression and confirms the presence of desired protein in the elution sample. Hence, 
fractions 6-8 were combined and buffer exchanged using a desalting column as previously 
discussed.  
The yield was recorded as follows: (assuming 40.57 kDa molecular weight and 28,420 
extinction coefficient parameters) 
0.340mg/ml of protein in 44ml of elution sample = 14.96mg 
The A260/A280 ratio was recorded as 1.100 (much higher than a 0.57 reading for pure 
protein53, due to excessive contamination being present). 
Figure 18: 
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3.2.3 IEX AKTA Graph  
The AKTA Graph, overviewing the elution stage of the IEX purification process can be 




In a similar method to the IMAC elution stage, the protein bound to the ion exchange 
column was eluted with an increasing salt concentration at a linear gradient, shown in 
green in Figure 20. The increasing salt displaces any bound protein as previously 
discussed. The gradient is seen to plateau at 100ml, having reached 100% salt 
concentration (1M NaCl). Additionally, the conductivity is also seen to increase at a linear 
gradient (as seen in red) due to being directly proportional to the salt concentration. A large 
UV peak is seen at 65ml, implying successful elution at a concentration of 650mM NaCl. 
Whilst this is high, it is expected as protein at pH = 8 is likely to bind tightly to the ion 
exchange column. The elution was collected in 5ml fractions. Fractions 15, 16, 17 and 18 


































Conductivity Gradient Concentration UV Fractions
Figure 20: 
TbrPDEB1 IEX Elution and Fractionation graph 
57 | P a g e  
 
3.2.4 IEX SDS-PAGE Gel 
An interpreted image of the SDS gel following secondary Nickel and IEX purification can 
be seen in Figure 21, with columns annotated as follows (from left to right): ladder, IMAC 
elution, untagged protein (secondary Nickel flow through + wash through), Tagged protein 





As observed in the IMAC SDS-PAGE Gel, the 40kDa value indicating desired TbrPDEB1 
protein persists throughout the next stages of purification (seen circled in red), implying 
the correct protein conditions have been met, as the protein was successfully isolated. This 
is confirmed by the lack of contamination peaks seen in bands F15 and F16. This also 
confirms the larger peak seen in the AKTA graph corresponding to desired protein. A lack 
of band circled in green suggest no TbrPDEB1 protein was present in the elution solution 
following secondary Nickel purification. This is due to no binding occurring between 
desired protein and the Nickel column as a result of cleavage of the histidine tag. In this 
case, the thrombin cleavage of the histidine tag is optimal. Despite some feint 
contamination bands being present in F17, the prominent 40kDa band indicates mainly 
TbrPDEB1 being present in the fraction, therefore the bands circled in red containing 
fractions F15, F16 and F17 were combined as the final purified protein sample. Sample 
F18 was discarded due to little desired protein present, and contaminants being present, 
especially at 75 kDa. The combined 15ml sample was concentrated and buffer exchanged 
accordingly, as previously discussed. The flow through is also seen to contain some 
Figure 21: 
TbrPDEB1 IEX SDS-PAGE Gel 
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desired protein, as circled in yellow. Hence, the collected flow through was also 
concentrated down and buffer exchanged, further adding to the overall yield, which was 
recorded as follows: 
A concentration of 0.71mg/ml after combining the appropriate fractions mentioned above, 
in 15ml volume. This results in: 
0.71 x 15 = 10.65mg of purified TbrPDEB1 protein. 
Additionally, 0.02mg/ml of TbrPDEB1 protein was found present within 98ml of flow 
through, resulting in an additional: 
0.02 x 98 = 1.96mg of desired protein. 
The flow through was extensively concentrated down and buffer exchanged and combined 
with the 10.65mg sample to yield: 
10.65 + 1.96 = 12.61mg of purified TbrPDEB1 protein with an A260/A280 ratio of 0.6. 
 
This purified protein yielded from a 2L culture was aliquoted appropriately as previously 
discussed and used for a number of screening experiments against the established fragment 
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3.3 Quality Control (QC) 
As previously mentioned, the fragment library put together by Dr. Fredrik Svensson from 
IOTA Pharmaceuticals consisting of 31 compounds (purchased from Enamine) first 
underwent quality control by 1D Proton (1H) NMR spectroscopy in order to ensure and 
verify optimal purity before undergoing experimentation with the purified TbrPDEB1 
protein. A list of this fragment set can be seen tabulated in Appendix 1 in the Appendices 
section at the end of the report. Hence, the 1D Proton NMR spectra and tabulated 
annotations can be seen for Ligands 6, 29 and 27. Similar information for the rest of the 
fragment library can also be found in the Appendices. 
 
3.3.1 Ligand 6 QC 




Additionally, an annotated table can be seen in Table 4 with assigned peaks seen in Figure 
23 on the following page. 
 
Figure 22: 
Ligand 6 Proton NMR QC Spectrum 




























Peak assignment Chemical shift (ppm) Splitting Corresponds to 
/ 0 Singlet TMS 
B 0.9 Triplet CH3 
C 1.75 Multiplet CH2 
/ 2.4 Triplet DMSOD6 
/ 3.4 Singlet Solvent peak 
F 3.9 Triplet CH2 
G 8.0 Singlet CH 
H 11.0 Singlet NH 
Figure 23: 
Ligand 6 assigned peaks 
Table 4: 
Ligand 6 Proton NMR annotated table 
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3.3.2 Ligand 29 QC 








Peak assignment Chemical shift (ppm) Splitting Corresponds to 
/ 2.4 Singlet DMSOD6 
/ 1.0 Singlets Impurity 
C 3.4 Singlet Solvent peak 
D 2.60 Singlet CH3 
E 2.79 Singlet CH3 
F 7.95 Doublet CH 
G 8.4 Doublet CH 
H 8.45 Singlet CH 
Figure 24: 
Ligand 29 Proton NMR QC Spectrum 
Table 5: 
Ligand 29 Proton NMR annotated table 













3.3.3 Ligand 27 QC 




Ligand 29 assigned peaks 
Figure 26: 
Ligand 27 Proton NMR QC Spectrum 
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Additionally, the manually acquired QC spectra agree with those provided by Enamine for 
each compound (unless specified with a corresponding impurity or solvent peak in the 










Peak assignment Chemical shift (ppm) Splitting Corresponds to 
/ 0 Singlet TMS 
/ 2.5 Singlet DMSOD6 
C 2.6 Singlet CH3 
D 3.4 Singlet Solvent peak 
E 4.5 Singlet CH2 
F 7.6 Triplet CH 
G 8.0 Triplet CH 
H 8.1 Doublet CH 
I 8.3 Doublet CH 
Figure 27: 
Ligand 27 Proton NMR QC Spectrum provided by Enamine 
Table 6: 
Ligand 27 Proton NMR annotated table 













As can be seen, a consistent solvent peak can be found in every Proton 1D spectrum at 
3.4ppm. The DMSOD6 solvent in which all compounds were dissolved in as previously 
mentioned was also analysed in order to determine all solvent peaks still present in 
compound spectra. This can be seen in Figure 29 below: 
 
Figure 28: 
Ligand 27 assigned peaks 
Figure 29: 
DMSOD6 Solvent Proton NMR Spectrum 
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As can be seen, the solvent peak is present at 2.4ppm in all compound spectra presented 
above. Additionally, a large water peak is also seen at 3.4ppm ± the same chemical shift as 
the consistent unknown peak. Additionally, Ligand 29 appears to be the only fragment in 
the set to contain any slight impurity, as shown in Figure 24 and Table 5 indicated by 
small singlet peaks at 1.0ppm. Ligand 29 was the only fragment to have underwent Proton 
1D experimentation several months following the rest of the fragment set, so perhaps this 
impurity is due to degradation of the solution stock. Nevertheless, the purchased fragment 
set is of ideal purity appropriate for use in fragment-based screening experiments, as 
determined by comparing against the provided NMR spectra by Enamine, characterising 
and interpreting the peaks, and identifying any impurities or solvent/water peaks present. 
All peak assignments were also checked and verified using ACD/C+H NMR Predictor72, 
an NMR analysis software. 
 
As previously mentioned, additional QC information can be found for the remaining 
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3.4 X-Ray Crystallography 
Following purification, the yielded TbrPDEB1 protein was crystallised as previously 
discussed, producing robust crystals 20ȝm in length, as can be seen in Figure 30 below. 
The protein crystals were used for X-Ray Crystallography experiments and were manually 
soaked with the library of 31 fragments used in this project (validated by QC NMR). 
Additionally, the XCHEM fragment screening approach previously mentioned was also 
done in parallel to manual crystal soaking in order to yield a wide variety of diffraction 
data used to assist in characterising, analysing and expanding the fragment library of 
known TbrPDEB1 binders used in this project by observing how each ligand interacts with 
the TbrPDEB1 protein at an atomic level, whilst also allowing comparison between the 
two methods of crystallisation. 
 
 Understanding how fragments are able to bind to the target protein is the first vital step in 
drug discovery by X-Ray Crystallography; Hence, before ligand evaluations can be made, 
















Crystallised TbrPDEB1 protein ± 20ȝm in length 
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3.4.1 Target Protein Apo Structure 
In the case of TbrPDEB1 for this project, the protein crystal apo structure is already known 
and publicly available in the Protein Data Bank54 (PDB, published by Wang, H and Ke, H), 
ZLWKWKH3'%FRGHµL¶DQG hence does not need to be solved. The PDB file displaying 
the 3D atomic structure in the case of the TbrPDEB1 catalytic domain protein structure, 
acquired from diffracting TbrPDEB1 crystals at 1.65Å resolution54, can also be acquired 
from the PDB and used for 3D structure visualization using a number of different 
softwares as previously mentioned. The quoted total structure weight of the full-length 
protein is reported as 77.628kDa54. The catalytic domain which hydrolyses cAMP to AMP 
as previously seen in Figure 4 is present between residues 668-905 and contains 16 alpha-
helices and 7 310-helices (types of secondary structures in polypeptides proteins). Note that 
the catalytic domain does not contain any beta-pleated sheets49. 
Hence, the published54 3D model is seen presented in Figure 31, created using PyMOL by 
















As can be seen, the asymmetric unit in Figure 31 contains two TbrPDEB1 molecules 
labelled as Chain A (right) and Chain B (left) which form a dimer in the crystal lattice49. 
Additionally, each chain is seen to contain two divalent metal ions ± Zinc (shown as a 
green sphere) and Magnesium (shown as a blue sphere). Unbonded water molecules in the 
structure are presented as red dots.  
 
Chain B Chain A 
Figure 31: 
TbrPDEB1 PDB Crystal structure overview ± 1.65Å ± Made 
with PyMOL 
68 | P a g e  
 
Furthermore, specific regions of interest in the TbrPDEB1 crystal structure include: 
1. Divalent Magnesium and Zinc metal ions 
2. M-loop 
3. Substrate binding pocket 
4. 3DUDVLWHVSHFLILFµP-pocket¶ 
 
These regions of interest are presented in a number of images in the case of Chain B as 
follows: 
The Magnesium and Zinc divalent metal ions present in the catalytic pocket of the 
TbrPDEB1 crystal structure serve an important role in enzyme biological function and 
activity. Metalloenzymes, in this case Zinc and Magnesium aid in catalysis by acting as 
Proton acceptors or Lewis acids. This aids in increasing polarity of chemical bonds and 
hence promote atom transfer56, particularly in the case of Zinc due to having a stable d10 
electron subshell ± making it stable in the Zn2+ electrophilic state and readily able to form 
metal complexes57. %HLQJDEOHWRIRUPZDWHUFRPSOH[HVPHWDOLRQVWKHUHIRUHDOVRµIUHHXS¶
the binding site for substrates57,58. In a 2009 metalloenzyme study by S. Maric et al59, 
1 - Figure 32: 
TbrPDEB1 PDB Crystal structure ± Divalent metal ions and water network ± 
Made with PyMOL 
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stripping a Malaria enzyme protein of Zinc by use of chelating agents such as EDTA 
causes a reported loss in enzyme activity by up to 57%. Upon addition of Zn2+ ions, an 
increase of enzymatic activity back to the original 100%59 was reported. In addition to 
aiding in enzymatic catalytic activity, metal ions are also important nutrients; Magnesium 
is required for DNA replication and other biological processes and aids in protein folding 
and interactions60. 
 
Looking at Figure 32 on the previous page, the divalent metal ions both form octahedral 
complexes; Zinc (green sphere) is seen to coordinate 2 Histidine (H) residues at positions 
673 and 709, 2 Aspartic acid (D) residues at positions 710 and 822 (shown in cyan) and 2 
water molecules (red spheres). Magnesium (blue sphere) is seen to also coordinate with 
Aspartic acid 710 and 5 water molecules49. These metal complexes are tightly bound and 
ensure enzymatic activity. 
The Aspartic acid, Arginine, Serine, Lysine, Asparagine, Methionine, Glutamic acid and 
Leucine amino acids ranging from residues 862-869 form the M-loop of the TbrPDEB1 
crystal structure, as seen presented in yellow in Figure 33. The M-loop plays a part in the 
formation of the parasite-VSHFLILFµ3-SRFNHW¶SUHVHQWLQWKHFU\VWDOVWUXFWXUHZKLFKZLOOEH
later discussed. Recent reports49 claim that the length of the M-loop influences the 
appearance of the P-pocket in Trypanosoma brucei, Trypanosoma cruzi and also in 
Leishmania major parasitic Phosphodiesterases49. 
2 - Figure 33: 
TbrPDEB1 PDB Crystal structure ± Labelled M-loop ± Made with PyMOL 
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Figure 34 shows the key points of interest in the TbrPDEB1 crystal structure. Firstly, the 
formation of M-loop (shown in yellow) is stabilized by the ʌ-ʌ stacking (caused by atomic 
orbital overlapping between atoms) non-covalent interactions between the benzene rings of 
Phenylalanine 844 and Phenylalanine 862, as shown in magenta49. This is similarly seen 
upon addition of a conjugated ring system substrate within the binding pocket, as will be 
discussed shortly. 
 
The binding pocket is present in-between the Phenylaniline 877 and Valine 840 residues, 
as shown in lime green in Figure 34. These moieties form a hydrophobic clamp, which is 
key for creating a preferential binding pocket. Due to the largely hydrophobic nature of 
phenylaniline and valine (according to the hydrophobic scales61), the two molecules have a 
tendency to attract to one other due to hydrophobic effect ± explained by the attraction of 
nonpolar molecules as a result of entropically favourable conditions. Additionally, the 
presence of an aromatic substrate within the clamp further ensues non-covalent interactions 
as a result of ʌ-ʌ stacking between the aromatic substrate and the PHE-844, and possibly 
PHE-877 residues62. This is the first key principle of ensuring ligand potency and binding 
to the protein structure, hence all ligands purchased and used for crystallography 
3 & 4 - Figure 34: 
TbrPDEB1 PDB Crystal structure ± Substrate binding pocket, Hydrophobic 
clamp, *OXWDPLQHZDWHUQHWZRUNDQG3DUDVLWHVSHFLILFµ3-SRFNHW¶± Made with 
PyMOL 
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experiments are seen to have an aromatic scaffold as they are considered µNQRZQPDE 
ELQGHUV¶. 
 
Another essential key principle for increasing ligand potency and binding strength is due to 
the presence of the Glutamine 874 µ4-VZLWFK¶ residue within the binding pocket, shown in 
navy blue in Figure 34. A water network is also present around this glutamine residue, as 
shown. Upon the addition of a substrate with a polar side chain, the glutamine is able to 
interact with the added ligand by hydrogen bonding, further increasing the binding strength 
of the compound within the binding pocket. The water molecules forming this additional 
network are displaced upon ligand uptake thus to allow this hydrogen bonding to occur49. 
Additionally, polar side chains being able to form multiple hydrogen bonds to this 
glutamine residue would increasingly strengthen protein-ligand interactions. The main 
point of interest presented in Figure 34 is the Parasite-VSHFLILFµ3-SRFNHW¶UHJLRQVKown in 
grey between the M-loop and Glutamine 874, formed by Alanine 837, Threonine 841, 
Tyrosine 845, Asparagine 867, Methionine 868, Glutamic acid 869 and Leucine 870 
residues33. The existence of this pocket may be exploited to give rise to phosphodiesterase 
inhibition specificity when targeting the parasitic enzyme. As previously discussed, due to 
the similarity in the binding pockets of human PDEs63 and parasitic PDEs, inhibition 
would be non-specific and would therefore be non-ideal and anti-therapeutic. Figure 35, 
adapted from a similar 2013 novel study on PDE crystal structures by Jansen et al49 depicts 















P-pocket region differences in TbrPDEB1 (A), LmjPDEB1 (B), 
TcrPDEC (C) and hPDE4B (D), adapted from a study by Jansen et al49 
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As can be seen, this pocket is seemingly only present in parasitic PDE structures, shown by 
the open density in Figure 35A-C, which is not present in the case of human PDE4B as 
seen in Figure 35D. Therefore, optimal compounds resulting in specific parasite PDE 
inhibition should contain an aromatic group and polar side chain scaffold in order to obtain 
ideal binding to the binding pocket, as well as large side chains capable of penetrating the 
empty density present in the P-pocket. In similar studies, such as the review by K. Orrling 
et al on Catechol Pyrazolinones as Trypanocidals62 and the Fragment-Based Drug 
Discovery of PDEs article by F. Svennson et al22, known human PDEs such as analogues 
of Rolipram and Sildenafil (otherwise known as Viagra) were used as starting scaffolds for 
parasitic PDE inhibitors. Slight variation in inhibitor chemotype was derived by methods 
such as virtual screening and molecular docking33 of suggested derivatives49. These were 
the main methods used to identify and evaluate parasite-specific inhibitors. Being the main 
structural difference between parasitic and human PDEs, this P-pocket cavity has been the 
main target of focus in this particular field of research33,49,62,22. 
 
As previously discussed in chapter 1.3, NPD-00833 was found to be a highly potent and 
partially selective TbrPDEB1 inhibitor. Figure 36 below, adapted from the mentioned 
2018 study by Blaazer et al33, shows the crystal structure of TbrPDEB1 with NPD-008 














NPD-008 bound to TbrPDEB1 protein structure, made with 
PyMOL using the 5G2B PDB Structure code33 
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7KLVLQKLELWRU¶VSRWHQF\LVLPPHGLDWHO\DSSDUHQWDVDUHVXOWRImultiple hydrogen bonds 
formed between the bound ligand, Glutamine 874, and other polar residues, as well as the 
previously discussed ʌ-ʌ stacking interactions in the substrate binding pocket. 
Additionally, the glycinamide tail of NPD-008 is also seen to form a hydrogen bond with 
the Glutamic acid 869 residue present in the P-pocket, successfully targeting the desired 
cavity and also achieving the desired therapeutic effect as previously shown in Figure 7 
and Figure 8. However, only a narrow inhibition selectivity was reported in TbrPDEB1 
over hPDE4, with clear cytotoxic effects of NPD-008 still being present against human 
MRC-5 cells33 (Medical Research Council cell strain 5). 
 
Hence, the fragment library used in this project will similarly be evaluated in terms of 
potency in order to identify any potential novel fragment binders to TbrPDEB1. 
 
3.4.2 Inhibitor Confirmation by X-Ray Crystallography 
Table 7 on the following page shows an overview of the ligand hits by X-Ray 
crystallography. As previously mentioned, varying ligand soak solution concentrations and 
soak durations were used throughout these experiments thus to have a wide variety of hit 
data and be able to best determine ideal binders by X-Ray Crystallography. Additional 
information is present in Appendix 30 for manual soak experiments and Appendix 31 for 
the XCHEM approach experiments. 
 
Note that the XCHEM crystallography experiments were only attempted once, and the 
entire library screen was not complete. However as can be seen in Table 7, double 
confirmations in the case of Ligands 1, 4 and 12 show promise in those particular 
structures as binders by X-Ray crystallography. The damaging of the crystal lattice or a 
poor resolution map result was very common in the case of crystallisation using the 
XCHEM approach; Reasons for this will be discussed later in this chapter. As previously 
mentioned, the major advantage of this approach is to screen large fragment libraries 
quickly and efficiently; Due to the small size of the fragment library used in this project, it 
is evident that the manual soaking technique ± despite being more time consuming ± 
overall served a better purpose for this particular task as it yielded more hits that were not 
apparent following the XCHEM approach. Nevertheless, the ability to compare and 
overlap the two techniques is undoubtably beneficial in the case of this research project. 
 
 








Ligand # Manual Soak Hit XCHEM Hit Ligand # Manual Soak Hit XCHEM Hit 
1 ᪵ ᪵ 17 ᪵ / 
2 ᪸ / 18 ᪸ / 
3 ᪵ / 19 ᪸ ᪸ 
4 ᪵ ᪵ 20 ᪸ / 
5 / ᪸ 21 ᪸ / 
6 ᪵ / 22 ᪵ / 
7 ᪸ / 23 ᪵ / 
8 ᪸ / 24 ᪸ / 
9 ᪵ ᪸ 25 ᪸ ᪸ 
10 ᪸ / 26 ᪸ / 
11 ᪸ / 27 ᪵ / 
12 ᪵ ᪵ 28 ᪸ / 
13 / / 29 ᪵ / 
14 / / 30 ᪸ ᪸ 
15 ᪸ ᪸ 31 / / 
16 ᪸ / 
 
Key: 
᪵ = Binder by X-Ray crystallography 
᪸ = Non-binder by X-Ray crystallography 
/ = Crystal damaged 
 
Hence, out of the 11 X-Ray Crystallography ligand hits, a number of successful binders are 
seen presented and discussed in greater detail in the following subheadings. The remaining 





Ligand hits by X-Ray Crystallography overview 
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3.4.2.1 Ligand 29 Data Analysis 
A TbrPDEB1 crystal soaked with Ligand 29 (ID Z45527541) at 40mM concentration for 











This crystal was diffracted at a resolution of 1.52Å and can be seen as collected on a 
Pilatus 6m image at the Diamond Light Source in Figure 38: 
 
Additionally, crystal details are further presented in Table 8 on the following page: 
Figure 38: 
TbrPDEB1 crystal soaked with Ligand 29 1.52Å diffraction 
Figure 37: 
TbrPDEB1 crystal soaked with Ligand 29 snapshot 
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Data collection -  
Synchrotron and Beamline Diamond Light Source, io4-1 
Space group C 1 2 1 
Molecules 2 
Cell dimensions 
a, b, c (Å) 
DEJq
 
115.70, 115.30, 68.60 













Refinement -  
Resolution (Å) 79.45 ± 1.46 
No. reflections 7532 
Rwork / Rfree 0.189 / 0.217 
No. atoms 5130 
R.m.s deviations 
Bond lengths (Å) 












X-Ray data collection and refinement statistics for TbrPDEB1-Lig29 complex 
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The crystallographic data collected for Ligand 29 was processed through the autoPROC 
SURFHVVLQJSLSHOLQHDWWKH'LDPRQG/LJKW6RXUFHJLYLQJDUHIOHFWLRQµPW]¶ILOH7KLV
reflection file was used to overlay the 4I15 PDB crystal structure for TbrPDEB1, and the 
map was solved accordingly. A green electron density (Fo-Fc omit difference map) in the 
preferential binding pocket of the crystal structure (present between Phenylalanine 877 and 
Valine 840, as previously discussed) implies a structural difference in the collected 
diffraction data in comparison to the model used; In other words, successful ligand binding 
is indicated as can be seen in Figure 39 at a 0.9 contour level, analysed with and created by 
















Following initial structural refinement, the ligand was modelled into the binding site using 
the appropriate smiles string shown in Appendix 1. Further refinement of the structure gave 
the final 3D interpretation of this protein-ligand complex as seen in Figure 40 on the 
following page. Note that structural information for Ligands 6, 27 and 29 can be seen in 




TbrPDEB1-Lig29 successful ligand binding, indicated by green 
electron density 
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Figure 40 depicts the binding mode of Ligand 29 in the TbrPDEB1 crystal structure 
binding pocket. As can be seen, the electrophilic sulphonamide tail group forms a 
surrounding water network by hydrogen bond formation. Surprisingly, the nitro group does 
not form a hydrogen bond with the invariant Glutamine 874. The likelihood of this is due 
to the ligand having a confirmation pointing away from this glutamine residue; The 
distance between the polar oxygen on the mentioned nitro group and the Glutamine residue 
is measured (using COOT) to be 5.74Å in length ± too large for the typical 1.5-2.5 
angstrom range of hydrogen bonds.  
Instead of Q-switch hydrogen bond formation, the ligand nitro oxygens form hydrogen 
bonds with the nitrogen atoms present on the Asparagine 825 and Valine 826 residues, 
3.78Å and 3.10Å in length, respectively. This hydrogen bond formation and water 
networks present maintain the ligand in the preferential binding pocket of the crystal 
structure. Whilst this is promising despite the lack of Glutamine 874 interaction, further 
protein-ligand binding determination experiments are required to validate Ligand 29 as a 
potential TbrPDEB1 binder.  
 
Figure 40: 
TbrPDEB1-Lig29 3D structure and binding from 3 different angles, made with PyMOL 
79 | P a g e  
 
3.4.2.2 Ligand 27 Data Analysis 
Similarly, Ligand 27 (ID Z220370518) was a successful hit in a soak concentration of 
50mM and a soak duration of 72 hours. The crystal details are seen presented in Table 9 
below: 
Data collection -  
Synchrotron and Beamline Diamond Light Source, io4-1 
Space group C 1 2 1 
Molecules 2 
Cell dimensions 
a, b, c (Å) 
DEJq
 
115.40, 114.77, 68.29 













Refinement -  
Resolution (Å) 79.24 ± 1.47 
No. reflections 6300 
Rwork / Rfree 0.244 / 0.270 
No. atoms 5130 
R.m.s deviations 
Bond lengths (Å) 






X-Ray data collection and refinement statistics for TbrPDEB1-Lig27 complex 
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Additionally, a 3D model interpretation of Ligand 27 binding to TbrPDEB1 is seen: 
 
 
As can be seen, Ligand 27 is well established within the TbrPDEB1 binding pocket. Like 
Ligand 29 in Figure 40, Ligand 27 forms a hydrogen bond water network. However, 
unlike the latter, Ligand 27 forms the essential hydrogen bond to the invariant Glutamine 
874 residue as previously discussed. The hydrogen bond, 3.20Å in length, is likely what 
JLYHVULVHWR/LJDQG¶VSRWHQF\DQGDELOLW\WRELQGWRWKHELQGLng pocket. Despite the 
successful bond formation, the acetonitrile tail of Ligand 27 points away from the parasite 
specific P-pocket; Therefore, if binding of this ligand to the protein target is to be 
confirmed by further means, it is highly expected that binding will be non-specific to the 
TbrPDEB1 target and inhibition to hPDE4D would also be observed. Of course, specific 
inhibition is not expected in the case of any fragments used in this project, as the purpose 
of these compounds was merely to determine their binding to TbrPDEB1, as they were 
originally selected by their tendency to inhibit hPDE enzymes. In any case, binding 
confirmation by other techniques is required in order to establish an active chemotype 






TbrPDEB1-Lig27 3D structure and binding made with PyMOL 
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3.4.2.3 Ligand 6 Data Analysis 





Data collection -  
Synchrotron and Beamline Diamond Light Source, io4-1 
Space group C 1 2 1 
Molecules 2 
Cell dimensions 
a, b, c (Å) 
DEJq
 
116.36, 115.17, 68.27 













Refinement -  
Resolution (Å) 79.70 ± 1.52 
No. reflections 6355 
Rwork / Rfree 0.188 / 0.212 
No. atoms 5130 
R.m.s deviations 
Bond lengths (Å) 











X-Ray data collection and refinement statistics for TbrPDEB1-Lig6 complex 
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In the case of Ligand 6, upon modelling the ligand within the crystal structure, varying 
electron densities remained present. Additionally, an average B-factor of atoms of 50.5 and 
an occupancy of 1.0 also suggests 50% occupancy of the ligand. In other words, it is 
present in the following position 50% of the time. This is due to the interchangeable 
binding confirmations of Ligand 6 to the substrate binding pocket, as depicted in Figure 
42. In the first binding confirmation (1), the oxygen on position 6 of the tetrahydro-1H-
purine-2,6-dione rings is seen to form a hydrogen bond 3.19Å in length to the invariant 
Glutamine Q-switch. In the second confirmation (2) the ligand is flipped 180° horizontally 
in order to create a new binding mode. In this binding mode, two hydrogen bond 
formations to the Glutamine Q-switch are suggested; the first by the same oxygen on 
position 6, forming a bond 3.55Å in length, and the second by the NH on position 1 
forming a weaker 3.34Å hydrogen bond (permanent dipole-permanent dipole interaction) 
Figure 42: 
TbrPDEB1-Lig6 3D structure and different binding modes (1 and 2) and 
binding mode overlap (3) made with PyMOL 
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to the nitrogen on the Glutamine residue. This interchangeable bond formation likely 
causes the latter confirmation to have preferred binding to the substrate binding pocket. 
The observed tetrahydro-1H-purine scaffold as seen in Ligand 6 is repeated across a 
number of X-Ray crystallography hits, including Ligand 3 and Ligand 9. Similarly, a close 
derivative chemotype including a quinazoline/chloroquinazoline scaffold, as seen in 
Ligands 12, 17, 22 and 29 are also found to be successful X-Ray hits. Figure 43 below 












As can be seen, the structure of IBMX is similar to that of the reported fragment hits to 
TbrPDEB1 (highlighted in red in Appendix 1) by X-Ray Crystallography. The aromatic 
tetrahydro-1H-purine-2,6-dione scaffold is a key characteristic across most hits, including 
Ligand 6 previously presented. Substitution of the 5-membered ring to a 6-membered ring, 
and variation between the position of the Nitrogen atoms give the Phthalazine and 
Quinazoline derivatives also identified as X-Ray hits in the case of the fragment library 
used in this project. In other words, it is no surprise that a majority of the set of compounds 
in Table 7 were identified by X-Ray crystallography, as the main scaffolds are very close 
derivatives of the potent non-selective hPDE inhibitor IBMX64 and are therefore not novel 
scaffolds. Nevertheless, the chemotype derivation of some hits to IBMX such as Ligand 29 
and understanding the binding interaction to the substrate binding pocket of TbrPDEB1 
remains an important task; Being able to confirm and identify compounds in this fragment 
Figure 43: 
Molecular structure of IBMX ± a known PDE Inhibitor 
Drawn on Chemsketch 
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library as active binders or potential TbrPDEB1 binders is still of upmost importance and 
remains the goal of this research project. 
 
Whilst the binding of known scaffold derivatives to the protein target is now understood in 
greater detail, the binding mode of Ligand 29 needs to be addressed in more detail. As 
previously mentioned, the importance of the invariant Glutamine Q-switch in parasitic (and 
human) Phosphodiesterases arises from substrate specificity determination.   
A 2004 article by K.Y.J. Zhang et al65 reports this Glutamine switch mechanism for 
nucleotide selectivity in the case of human Phosphodiesterases. The article discusses the 
Glutamine-874 residue recognising and forming essential hydrogen bonds to the purine 
ring present in the cAMP and cGMP substrates and additionally in the fragment hits. This 
glutamine residue is able to adopt two different orientations65 thus enabling substrate dual-
specificity (in the case of hPDE1B as an example). In the case of the cAMP-specific 
TbrPDEB1, the glutamine residue possesses only one confirmation. Upon inhibitor binding 
to the active site, glutamine hydrogen bond formation is important because of this 
selectivity mechanism. An already occupied binding site / glutamine residue would prevent 
cAMP from entering the binding site and in turn the catalytic hydrolysis reaction 
(assuming a potent enough inhibitor thus to not be displaced by the cAMP substrate). The 
interesting phenomenon in the case of Ligand 29 is the lack of this glutamine occupation 
occurring. Instead, the ligand binds to the Asparagine 825 and Valine 826 residues as 
previously mentioned; However, the high concentration crystal soaks and confirmed ligand 
binding by X-Ray crystallography is slightly biased and insufficient to determine whether a 
ligand truly has a binding affinity, or how potent it is. Simply put, the aim of X-Ray 
crystallography is only to get a general idea of whether a particular ligand chemotype is 
Figure 44: 
Molecular structures of cAMP (left) and cGMP (right) drawn on Chemsketch 
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capable of binding by extreme methods ± a high soak concentration / prolonged soak 
duration as well as observing the binding interactions. How well a ligand occupies the 
binding site and competes over the natural cAMP substrate in solution (a more medically 
realistic view) cannot be determined by X-Ray crystallography. Therefore, the X-Ray hits 
are further screened and validated by other Biophysical / Biochemical techniques, as will 
be discussed in the following chapters. This way, the Ligand 29 binding interaction can be 
examined further by determining the fragment potency.  
 
3.4.3 XCHEM Data Analysis 
Looking at Appendix 30 and Appendix 31 (and Table 7), it is evident that the hit overview 
comparison between the two techniques does not match. Out of the 31 fragments screened 
in total, 11 proved to be identified hits by manual soaking, in comparison to 3 successful 
hits as a result of the XCHEM approach. In the case of poor binding ligands, soak 
concentration and soak duration were both increased in the case of manual crystallisation 
in order to test fragments which had not damaged the crystal, as optimal diffraction seemed 
to occur but appeared to possess a very weak binding affinity as there was no electron 
density present in the binding pocket. Comparing this to the XCHEM approach, a large 
number of binders by manual crystallisation such as Ligands 22, 27 and 29 which showed 
promising Fo ± Fc difference maps and even binding affinity confirmation by Biochemical 
assays and NMR (as seen in the following chapters) did not appear as X-Ray hits in the 
XCHEM approach. The reason for this is because in most cases, the crystal was either 
destroyed by the ligand soak or yielded a very poor resolution or an incorrect space group, 
which is a clear indication of crystal damage occurring. To recap on soak details in both 
techniques: 
 
As previously mentioned, 2 super stocks of 100mM and 400mM concentration were made 
up for all 31 compounds. The 400mM super stock was used to make 30mM, 40mM and 
50mM manual soak solutions. Note that the ligand super stocks were made up with 100% 
DMSO, which is capable of heavily damaging the lattice of a crystal at high 
concentrations. Making a 40mM concentrated solution from the 400mM stock would result 
in a total of 10% DMSO being present in the soak solution, which appears to be 
appropriate due to a lack of crystal damage as observed in the manual soaking overview.  
Note that prior to the XCHEM screening experiment, TbrPDEB1 crystals were initially 
soaked in a range of DMSO concentrations from 5% to 40% DMSO content within a 
crystal drop, thus to observe the limits of crystal survival. Crystals appeared to survive up 
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to a 40% DMSO concentration, however some crystal damage was observed at 40% 
indicated by slightly higher (and therefore poorer) resolution maps.  
 
The actual XCHEM fragment screen was performed by dispensing appropriate nanolitre 
drops of 100mM fragment stocks into 400nanolitre crystal drops using an ECHO dispenser 
to reach the desired soak concentration. Due to using a 100mM stock, the DMSO 
concentration was 40% instead of 10% as seen in the case of manual soaks. Despite a 40% 
DMSO concentration being seemingly appropriate following the DMSO crystal survival 
rate experiment, the question is whether a high DMSO concentration and a high binding 
affinity ligand in combination has a more damaging effect on a TbrPDEB1 crystal 
compared to just a high DMSO concentration alone. Going back to the XCHEM hit rate 
taking this into account, this is a more plausible explanation as the only XCHEM hits 
(Ligands 1, 3 and 12) were weak binders as indicated by Biochemical assays and NMR in 
the following chapters. Essentially, a low stock concentration (high DMSO concentration) 
destroys crystals in the case of higher binding affinity ligands. To put this hypothesis to the 
test, it would be ideal to repeat the XCHEM fragment screen approach with the same 
conditions as the manual soaking experiments (30mM and 40mM soaks from a 400mM 
stock for 24 hours) and observe whether the same hits are determined. Additionally, a 
separate experiment can be ran in parallel using a high soak concentration (100mM from a 
400mM stock) for a much shorter duration, such as 3 hours, in order to best optimise the 
XCHEM procedure and observe successful ligand hits and the crystal survival rate, as it is 
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3.5 Luciferase Biochemical Assays 
As previously discussed in section 2.6, the PDE4NPD Standard Operating Procedures 
protocol was followed after slight adaptation for the determination of a suitable working 
PDE concentration and single concentration assessment experiments of new compounds.  
 
3.5.1 Determining a suitable TbrPDEB1 concentration 
Before the identified X-Ray crystallography fragment hits can be screened further, the 
Biochemical assay must initially be optimised by using a wide range of TbrPDEB1 
concentrations thus to give suitable readings according to the positive and negative 
controls used. Initially, the PDE4NPD protocol followed advised using a range of 
concentrations starting from a 1:10 PDE dilution and continuing the series in a ten-fold 
dilution until a 1:100,000 dilution was reached. This protocol was slightly adapted, as the 
1:10 TbrPDEB1 dilution seemed to be in excess due to giving much higher RLU (Relative 
Light Unit) values compared to the AMP positive control and was therefore discarded from 
the series; This was questionable initially, as it seems invalid that the RLU value of a 
certain dilution was greater than that of the theoretical maximum RLU value. However, it 
was suspected that the presence of TbrPDEB1 protein in excess also contributed to 
detected AMP, and hence resulted in increased RLU values.  
Additionally, note that a multi-channel pipette was used to simultaneously add the cAMP 
reagent to every microplate well in order to initiate the hydrolysis reaction as seen in 
Figure 4 at the same time, thus to reduce error in readings and produce more reliable data. 
Also note that the initial 1:1 concentration was used at 1mg/ml of TbrPDEB1 protein.  
 
Figure 45 on the following page shows a graph depicting the RLU values measured for 
each TbrPDEB1 dilution: 





As can be seen, the positive control initially rises and slowly begins to decreases following 
the maximum RLU reading. Initially, the positive control gives the highest light reading, 
however the 1:100 dilution is seen to surpass this indicating that perhaps this dilution is 
also in excess. The PDE4NPD protocol instructs to use a dilution that is in the linear range 
and gives 25% of the maximum RLU value (given by the AMP control) after 20 minutes. 
The 1:300 dilution is an ideal candidate for this, as it appears linear on the graph; 
Additionally, the 1:300 dilution gives an RLU value of 27779 after 20 minutes ± 22.5% of 
the measured 123384.5 RLU value of the positive AMP control after 20 minutes. An 
additional change made to the original protocol can be seen in the dilutions chosen for the 
series: Instead of following a ten-fold series from 1:10 to 1:100,000, 1:300 and 1:500 were 
also added to the series. This was done due to the 25% of the maximum RLU value target 
being observed somewhere between the 1:100 and 1:1000 dilution range, hence an 
additional 2 dilutions were added in order to increase accuracy. The 1:100,000 dilution was 
also discarded as it is too dilute, as the 1:10,000 dilution is seen to be very close to the 
negative control in Figure 45. Additionally, TbrPDEB1 enzyme activity is also confirmed. 
Hence, the determined optimal TbrPDEB1 concentration of 1:300 was then used to run the 
assay screen against the identified X-Ray crystallography hits from the previous chapter. 
Figure 45: 
Determination of a suitable working TbrPDEB1 














Determining a suitable working TbrPDEB1 concentration
1 to 100 1 to 300 1 to 500 1 to 1000
1 to 10,000 Positive Control Negative Control
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3.5.2 Single concentration assessment of identified X-Ray Fragment Hits 
against TbrPDEB1 
100mM DMSO stocks of Ligands 1, 3, 4, 6, 9, 12, 17, 22, 23, 27 and 29 (X-Ray 
Crystallography hits) were used to prepare the appropriate ligand concentration solution 
dissolved in Stimulation Buffer + 6% DMSO. The recommended ligand concentration in 
the PDE4NPD protocol was determined to be 60ȝM; However, this protocol was initially 
designed to assess officially selected PDE4NPD compounds synthesised to yield as much 
potency as possible. In the case of this project, mere fragments are being assessed therefore 
it is expected that the potency yield would be much lower. Hence, an increased ligand 
concentration of 200ȝM was used instead. NPD-008, a known potent TbrPDEB1 inhibitor 
previously mentioned in this report was used as a control in this experiment. Fragment 
inhibition of the TbrPDEB1 target, if any, was compared to the NPD-008 control. Figure 
46 shows a graph depicting the RLU values measured for each Ligand (at a 200ȝM 
concentration) in TbrPDEB1 protein (diluted to 1:300 from an initial concentration of 
1mg/ml) over a 55-minute period. NPD-008 inhibitor, and no inhibitor at all are two 
controls used in addition to the positive (AMP instead of cAMP) and negative (Stimulation 

















Assessment of identified X-Ray Hits against TbrPDEB1
L1 L3 L4 L6 L9
L12 L17 L22 L23 L27
L29 NPD-008 No TbrPDEB1 No Inhibitor AMP
Figure 46: 
Assessment screen of X-Ray fragment hits against determined optimal TbrPDEB1 
concentration by use of a Biochemical Assay 
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The remaining activity can be calculated and normalised using the following equation at a 
selected time point of 20 minutes: 
 
Remaining activity = ሺௌ௔௠௣௟௘௩௔௟௨௘ିᇲே௢ܾܶݎܲܦா஻ଵᇲ௖௢௡௧௥௢௟ሻሺᇱே௢ூ௡௛௜௕௜௧௢௥ᇲ௖௢௡௧௥௢௟ିᇲே௢்௕௥௉஽ா஻ଵᇲ௖௢௡௧௥௢௟ሻ ݔ ? ? ? ? 
 
The remaining activity of each ligand was calculated as seen in Table 11. Additionally, the 
percentage inhibition is also seen, calculated using the following equation: 
 
Maximum inhibition (%) = 100% - Remaining Activity (%) 
Sample Remaining Activity (%) Maximum Inhibition (%) 
Ligand 1 183.74 -83.74 
Ligand 3 143.735 -43.735 
Ligand 4 162.44 -62.44 
Ligand 6 138.98 -38.98 
Ligand 9 136.77 -36.77 
Ligand 12 146.95 -46.95 
Ligand 17 139.12 -39.12 
Ligand 22 97.89 2.11 
Ligand 23 105.8 -5.8 
Ligand 27 89.5 10.5 
Ligand 29 87.14 12.86 
NPD-008 3.64 96.36 
No TbrPDEB1 0 100 
No Inhibitor 100 0 
 
The Remaining Activity for each sample can also be seen in graph form in Figure 47 on 





Biochemical Assay determined inhibition of X-Ray hits and controls to 
TbrPDEB1 





As can be seen, the quality of the screen looks promising: The high concentration of the 
NPD-008 control yields almost total inhibition of the TbrPDEB1 target enzyme. 
Additionally, Ligand 29 also shows great promise as it yields the highest Maximum 
Inhibition percentage out of the other ligands at 12.86% inhibition. This seems incredibly 
minor compared to the 96.36% inhibition of NPD-008 - however keeping in mind that 
Ligand 29 is an unrefined fragment it is still promising that a small level of inhibition is 
observed. Ligand 27 also shows a 10.5% maximum inhibition. The majority of the other 
ligands show Remaining Activity above 100% due to errors common in Biochemical 
assays. Despite being successful binders in X-Ray Crystallography, it is apparent that 
actually in solution most fragments in the set are not potent enough to be able to compete 
against the cAMP substrate or displace it from the TbrPDEB1 binding site to yield any 
inhibition.  
 
Additionally, the screen was repeated against the hPDE4D protein target in order to 





























Remaining TbrPDEB1 activity at  ? ? ?ʅD&ƌĂŐŵĞŶƚ
Concentration
Figure 47: 
Remaining TbrPDEB1 activity at 200ȝ0 X-Ray Fragment Hit 
Concentration in graph form 
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3.5.3 Determining a suitable hPDE4D concentration 
The protocol used in section 3.4.1 was repeated in the case of hPDE4D for the purpose of 
optimization and determining an optimal protein concentration to be used for the screening 




As can be seen, a different dilution range is used for this particular assay. Initially, the 
1:300 dilution from a starting concentration of 1mg/ml used in the case of the TbrPDEB1 
optimization assay was also used for the hPDE4D screen. However, this was incorrect as 
this assumes both enzymes are of equal activity, which gave an error in the assay as RLU 
limit detection was being hit very quickly due to the protein being in excess. Hence, the 
1:50,000 and 1:100,000 dilutions were also added to this assay after it was made evident 
that this particular enzyme is much more active and hence requires far less PDE to reach a 
suitable concentration. It was determined that the 1:10,000 dilution was best suited (from a 
starting concentration of 1mg/ml) for an assay screen, as it is within a linear range and also 
gives an RLU value of around 25% compared to the RLU value given by the positive 
control at 20 minutes, as seen highlighted. Hence, this particular dilution was used to run 


















Determining a suitable working hPDE4D concentration 
1 to 100 1 to 300 1 to 500
1 to 1000 1 to 10,000 1 to 50,000
1 to 100,000 Negative Control Positive Control
Figure 48: 
Determination of a suitable working hPDE4D 
concentration by use of a Biochemical Assay 
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3.5.4 Single concentration assessment of identified X-Ray Fragment Hits 
against hPDE4D 
The protocol used in section 3.4.2 was also repeated at 200ȝM fragment concentration 
against hPDE4D protein target at a 1:10,000 dilution from an initial concentration of 
1mg/ml. The purpose of this experiment was to confirm previous speculations on how this 
particular fragment library would interact with hPDE4D. A similar graph depicting the 
RLU values measured for each ligand in hPDE4D protein over a 55-minute period can be 
seen in Figure 49 below: 
 
The remaining activity and maximum inhibition of each ligand were also calculated as 
























Assessment of identified X-Ray Hits against hPDE4D
L1 L3 L4 L6 L9
L12 L17 L22 L23 L27
L29 NPD-008 No hPDE4D No Inhibitor
Figure 49: 
Assessment screen of X-Ray fragment hits against determined optimal hPDE4D 
concentration by use of a Biochemical Assay 


























Remaining hPDE4D activity at 200ʅD&ƌĂŐŵĞŶƚŽŶĐĞŶƚƌĂƚŝŽŶ
 
Sample Remaining Activity (%) Maximum Inhibition (%) 
Ligand 1 1.23 98.77 
Ligand 3 8.27 91.73 
Ligand 4 1.58 98.42 
Ligand 6 0.13 99.87 
Ligand 9 20.56 79.44 
Ligand 12 55.07 44.93 
Ligand 17 115.99 -15.99 
Ligand 22 32.94 67.06 
Ligand 23 19.26 80.74 
Ligand 27 23.65 76.35 
Ligand 29 -2.4 102.4 
NPD-008 9.32 90.68 
No hPDE4D 0 100 
No Inhibitor 100 0 
 




Biochemical Assay determined inhibition of X-Ray hits and controls to 
hPDE4D 
Figure 50: 
Remaining hPDE4D activity at 200ȝ0 X-Ray Fragment Hit 
Concentration in graph form 
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As can be seen, the assay screen results are as expected; At an optimal enzyme 
concentration, it appears that most ligands used in the screen almost completely inhibit 
hPDE4D at 200ȝM inhibitor concentration. It is observed that the NPD-008 control also 
yields a 90.68% inhibition - slightly less than the 96.36% inhibition measured against 
TbrPDEB1, showing that NPD-008 is indeed slightly selective against the desired target, 
however not to a degree of optimal selectivity to advance to further trials, as concluded by 
previously cited literature33.  
 
As previously mentioned, the fragment library was put together based on their potency 
against human PDE enzymes. Table 13 below shows the Ki and IC50 values for every 
fragment used in this particular screen against hPDE4D as reported from ChemBL47. Ki is 
an inhibitor dissociation constant indicating inhibitor potency and the functional strength 
of an inhibitor; The lower the Ki value, the greater the binding affinity of a particular 
inhibitor. The IC50 (half maximal inhibitory concentration) of an inhibitor measures the 
concentration required of a potent compound to give a 50% inhibition response. This can 
be generated using dose response curves of a particular compound, similarly to the single 
concentration fragment assessment assays as previously presented, instead using a range of 
inhibitor concentrations as will be later discussed. 
 
Lig # 1 3 4 6 9 12 17 22 23 27 29 
Ki / 36500 / 43100 63000 / / / / / / 
IC50 14,000 / 520 / / / / 231 / / 1800 
 
These values may be compared to measured IC50 data against the TbrPDEB1 target for 
several fragments following assays generating dose response curves. Ligands 29 and 27 are 
ideal candidates for this experiment, as both fragments yielded the highest inhibition 
against TbrPDEB1. Whilst both ligands also yielded high inhibition against hPDE4D, 
Ligand 27 yielded significantly less (around 30%) compared to Ligand 29, making it an 
increasingly attractive candidate as it also possesses the essential Q-switch binding as 
previously discussed. The lack of Q-switch binding of Ligand 29 and large measured 
inhibition against both targets would also be of interest to compare to Ligand 27.  
However, before these assay experiments can be carried out, it is necessary to determine a 
Km value for TbrPDEB1. 
Table 13: 
ChemBL Reported IC50 and Ki values of fragments against hPDE4D (ȝM) 
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3.5.5 Km determination of TbrPDEB1 
A similar protocol as seen in section 3.4.1 was used for this experiment, with the exception 
of using a set TbrPDEB1 concentration (at a 1:300 dilution as determined by the previous 
optimisation assay). Instead, a range of cAMP substrate concentrations were used, as 
follows: 0ȝM, 0.625ȝM, 1.25ȝM, 2.5ȝM, 5ȝM, 10ȝM, 20ȝM and 40ȝM. A suitable time 
point was chosen for analysis, determined by observing the point of RLU signal saturation. 
This time point was used to plot a graph in order to calculate Km, as seen in Figure 51 
below. A Km value is derived from and used in Michaelis-Menten enzyme kinetics. Km is 
a measurement of the concentration of substrate required to achieve half of the maximum 
enzymatic response, described by ½ Vmax (in this case, half of the maximum RLU value). 
In other words, Km can be used to represent the overall enzyme efficiency by determining 
the rate at which the enzyme is capable of binding to the substrate, and hence the overall  
enzyme-substrate affinity. A low Km implies the enzyme has a higher affinity towards the 
substrate, and vice versa. In this case, the Vmax is observed to be 72,024 RLUs as seen in 





By taking the relevant equivalence point, 36,012 RLUs is equivalent to 13.5ȝM cAMP 
substrate concentration. Compared to the recorded 1.19 Km value of TbrPDEB1 in the 
















Km determination of TbrPDEB1 
Figure 51: 
TbrPDEB1 enzyme Km determination Biochemical assay 
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to enzyme activity variability; As previously shown, a 1:300 dilution was required to give 
optimal linear results for the Biochemical assay optimisation, which also implies a less 
active enzyme. Nevertheless, Dose response curve calculations can be appropriately 
adjusted using the newly recorded Km value. 
 
3.5.6 Dose response curve Biochemical assays 
With the optimised cAMP substrate and target protein concentration, dose response curves 
were ran following the TbrPDEB1 fragment screen. 10mM stock solutions were prepared 
for the appropriate compounds being tested. 6% of ligand stock solutions were mixed in a 
total 100ȝl of stimulation buffer in the first row of a Corning 96-well plate resulting in a 
6x10-4M or 600ȝM concentration. The serial dilution continued to a final concentration of 
6x10-10M or 0.6nanomolar, with the last row of the plate consisting of 6% DMSO control 
in a total of 100ȝl of stimulation buffer. 17.5ȝl of the compound solution wells was 
transferred to a fresh Corning 96-well plate with a multichannel pipette and the procedure 
continued as described previously. The plate was read for a total of 55 minutes, and a 
suitable time point was chosen for analysis for each curve. Additionally, a positive and 
negative control were also ran as seen in previous assays. The cAMP substrate 
concentration remained at 10ȝM, just slightly below the calculated Km value of 13.5ȝM. 
The protein dilution also remained at 1:300. The purpose of these assay experiment was to 
determine the IC50 of the most promising fragments as identified by X-Ray crystallography 
and previous Biochemical assays by observing the particular concentration range where an 
inhibition response is seen. 
 
Hence, Ligand 27 and Ligand 29, with the addition of NPD-008 as a control were tested in 
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3.5.6.1 Ligand 29 Dose response curve 
The assay experiment curve can be seen in Figure 52 below: Note that the logarithm of the 
inhibitor concentration range was used for the x-axis. 
 
 
As can be seen, no real trend can be deduced from this particular curve. The decreasing 
RLU value does not seem to be proportional with increasing inhibitor concentration as 
would be expected with a potent inhibitor. The RLU fluctuation is likely due to assay 
reading errors, as in this case measured inhibition is practically non-existent. As previously 
seen in section 3.5.2, 12.86% inhibition of TbrPDEB1 was measured in the case of Ligand 
29 at 200ȝM concentration. At the beginning of the serial dilution (600ȝM or log[-
3.22M]), the inhibitor is likely in excess, and inhibition past this concentration would be 
very difficult to observe. In other words, despite yielding the most inhibition against 
TbrPDEB1, this compound is simply not potent enough to be viable for dose response 

















Ligand 29 Dose Response Curve
Figure 52: 
Ligand 29 dose response curve against TbrPDEB1 
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3.5.6.2 Ligand 27 Dose response curve 
This is similarly seen in the case of Ligand 27, as can be seen in Figure 53 below: 
 
 
As previously mentioned, a Dose response curve was also produced using NPD-008 as a 
























Ligand 27 Dose Response Curve
Figure 53: 
Ligand 27 dose response curve against TbrPDEB1 
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In the case of NPD-008, the curve is clearly seen, and a concentration point at which an 
inhibition effect is observed can be seen. The IC50 can be seen in Table 14, calculated by 








The IC50 is calculated to be 5.23x10-6M, or 5.23ȝM. This agrees with the reported IC50 
value of NPD-008 of 5.5ȝM against TbrPDEB1 as seen in the previously cited article by 
A.R. Blaazer et al33 on a similar study. This in turn increases confidence in the dose 






















NPD-008 Dose Response Curve
Figure 54: 
NPD-008 dose response curve against TbrPDEB1 
Table 14: 
NPD-008 IC50 table 
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A lack of compound potency in the case of Ligands 29 and 27 is due to ineffective binding 
to the TbrPDEB1 substrate binding pocket compared to cAMP substrate. However, this is 
expected in the case of fragments. Nevertheless, novel fragments capable of binding to 
TbrPDEB1 have been identified within this research project. Despite not showing optimal 
WDUJHWLQKLELWLRQWKLVLVVWLOOEHQHILFLDODVWKHµFKHUU\-SLFNHG¶ELQGHUVIURPWKHVWDUWLQJ
fragment library can be modified in future work thus to increase potency and in turn 
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3.6 Ligand-Protein NMR 
The final screening method used in this project was through several NMR techniques ideal 
for observing protein-ligand interactions. The purpose of this additional technique is to 
support the results yielded from the Biochemical assays by being able to identify fragment 
binding to the TbrPDEB1 target. Like the Biochemical assay screen, this technique can 
quantitatively measure ligand binding affinity to the protein target indirectly by exploiting 
several NMR techniques such as the Nuclear Overhauser Effect (NOE), as will be later 
discussed. Table 15 below shows a brief overview of the X-Ray Crystallisation hits 





Ligand # WaterLOGSY Hit STD Hit CPMG Hit 
1 ᪵ ᪵ ᪵ 
3 ᪸ ᪸ ᪸ 
4 ᪵ ᪸ ᪵ 
6 ᪸ ᪸ ᪸ 
9 ᪸ ᪵ ᪸ 
12 ᪸ ᪸ ᪵ 
17 ᪸ ᪸ ᪸ 
22 ᪸ ᪸ ᪵ 
23 ᪸ ᪸ ᪸ 
27 ᪸ ᪸ ᪸ 
29 ᪵ ᪵ ᪵ 
 
 








Overview of X-Ray Crystallography hits screened by various protein-
ligand NMR techniques 
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3.6.1 TbrPDEB1 1D Proton NMR Spectrum 
A simple 1D Proton NMR experiment was ran on the TbrPDEB1 target protein as 
previously mentioned in section 2.8.2. The respective spectrum yielded from this 




As can be seen, a 1H NMR spectrum of a folded protein is far more complex in 
comparison to simple molecules or fragments and contains many regions of interest. The 
jagged peak regions between 6.5-8.5ppm correspond to the amide NH hydrogens present in 
the peptide backbone and amino acid side chain residues of the protein. The region 
between 6.5-7.5ppm also corresponds to the aromatic rings present in amino acid residues. 
The inverted peak as seen at 4.5ppm is an artefact as a result of water suppression on the 
spectrum. Another key region common in folded proteins is seen between 0.5-2ppm region 
corresponding to hydrogen atoms present on CH3 methyl side chains. Additionally, the 
peaks seen between 2.2-3ppm also correspond to the open, aliphatic hydrocarbon chains. A 
large impurity peak is seen 3.7ppm; This impurity peak was identified as remaining 
glycerol present in the protein sample from the previous storage buffer. Despite excessive 
buffer exchanging, the glycerol remained abundant, yielding a large impurity peak present 
Figure 55: 
TbrPDEB1 protein Proton 1D NMR Spectrum 
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in the protein sample. A 1D Proton NMR spectrum of glycerol was determined as can be 

















TbrPDEB1 Proton 1D NMR spectrum impurity (left) and glycerol 
Proton 1D NMR spectrum (right) 
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3.6.2 Protein-Ligand Interaction NMR 
Whilst it is promising to obtain validation of the target protein integrity by 1H NMR, it is 
not beneficial in terms of protein-ligand interaction experiments. As previously mentioned 
in section 2.8.3, the samples tested for the protein-ligand experiments consisted of 0.5mM 
ligand and 0.01mM protein. At such a low concentration, protein peaks would be 
incredibly feint and difficult to distinguish. Instead, binding affinity can be observed by 
comparing ligand behaviour in presence of protein against a ligand solution with the same 
concentration. These ligand-based screening approaches rely on fast dissociation of bound 
ligands and measuring the Nuclear Overhauser Effect (NOE) relaxation time in order to 
observe differences between protein-ligand and ligand spectra73. These experiments are 
ideal for fragments, as a low affinity to the protein target is expected and also required in 
order to achieve a rapid exchange between the bound and unbound forms. In other words, 
high affinity / tightly bound ligands would have a very short or no dissociation from the 
protein structure at all and would therefore not be ideal for these experiments. 
 
These particular techniques are based on observing the intensity of magnetization 
transferred to the free, unbound ligand state by the protein-bound ligand protons74. Again, 
note that both of these states are in constant exchange due to the rapid dissociation from 
the protein-bound to the unbound ligand state. It is expected that a small molecular weight 
molecule such as a fragment would have a small positive NOE value, whilst a larger 
molecule such as a 40.57kDA protein would have a large negative NOE value74. Upon 
ligand binding to the protein, the magnetization transfer to the ligand in bound state 
following excitation on the protein would also cause it to acquire a large negative NOE 
state. Upon dissociation, the new NOE state of unbound ligand differs from its original 
small positive NOE value. This change in NOE values as a result of magnetization 
transferred is indirectly proportional to ligand-protein binding. The observed response is 
dependent on the quantity of unbound ligand experiencing a magnetization transfer, which 
in turn is dependent on the quantity of unbound ligand bound to the protein to begin with74. 
Hence, binding affinity can be indirectly and quantitatively observed. 
 
The techniques used are discussed in greater detail and presented in the case of Ligand 29 
and Ligand 27 in the following pages. The NMR spectra of the other ligands can be seen 
presented from Appendix 41 to Appendix 67 in the Appendices.  
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3.6.2.1 Ligand 29 waterLOGSY NMR 
This particular experiment uses a phenomenon similar to that previously described above, 
however the transfer arises from bulk water magnetization. In other words, present water 
molecules in the protein-ligand sample are excited and transfer a bulk magnetization 
moment to the protein. This in turn is transferred to the ligand74; The difference in 
magnetization can be quantified upon dissociation as previously discussed. In this case, the 
observed response would be a resonance with opposing peaks in the case of bound 
compounds74. This can be seen in Figure 57, depicting the waterLOGSY NMR spectra for 
Ligand 29. 
As can be seen, Ligand 29 peaks (seen present in the reference spectrum in green) are seen 
inverted in the Ligand 29-TbrPDEB1 waterLOGSY spectrum in blue. The spectrum in red 
is another waterLOGSY experiment performed on a ligand sample outside of protein 
solution, in order to normalise the signal intensity as the ligand can directly acquire 
magnetisation from the bulk solvent present in the sample which can lead to false 
positives74. In order to correctly compare each spectrum, the phases and baselines of all 
spectra were corrected and normalized. The line broadening was also corrected to a value 
Figure 57: 
Ligand 29-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D spectrum 
(Top), Ligand 29 Control WaterLOGSY spectrum (Middle), Ligand-Protein 
WaterLOGSY spectrum (Bottom) 
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of 3hz. In the case of Ligand 29, a successful hit can be seen for the waterLOGSY 
experiment. Note however, that the 1D Proton spectrum in green may vary from the 1D 
Proton spectrum determined from the Compound QC as a result of a different solvent 
being present, and the possibility of peak shifting to occur. The 1D NMR Proton spectrum 
of the phosphate solvent used to make up each solution can be seen in Appendix 40; 
however, no impurities appear to be present. Despite this, the purpose of the previous QC 
experiments was simply to verify the purity of each compound prior to any further 
experimentation. Since no compounds were flagged as a result of a questionable purity due 
to excessive contamination, peak identification in the case of Protein-Ligand experiments 
are not as vital. 
 
3.6.2.2 Ligand 29 STD NMR 
Similarly, Saturation Transfer Difference NMR works by initially saturating a protein by 
exciting a local region, which in turn affects the spin states of the protons on the entire 
protein, including the binding site hydrogens. Bound ligand protons would also experience 
this change in polarization, and in turn the unbound state ligand hydrogens, causing the 
response to be quantitatively measured as previously discussed74 and observed by a 
reduced signal on the spectrum. In addition to protein saturation, another experiment is ran 
simultaneously where an off-resonance region is excited, thus not saturating the protein. 
The purpose of this is to cancel out any background noise once a difference spectrum is 
taken, leaving only peaks of any molecule that has at some point experienced a change in 
magnetization and hence an association to the protein. In other words, in the case of a 
bound ligand, low intensity peaks would be observed in the difference spectrum. An empty 
difference spectrum is a result of no magnetization transfer occurring due to unsuccessful 
ligand binding75 and cancelling out of the on-resonance and off-resonance spectra. This is 
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As can be seen, ligand-protein binding is indicated by STD NMR due to reduced intensity 
ligand peaks being present in the difference spectrum (in blue), implying a successful 
magnetization transfer on the ligand occurring. Like in the waterLOGSY experiment, the 
phases were adjusted so that they are equal, and the line broadening was increased to 3hz.  
 
An STD experiment was also performed on the ligand solution, as seen in Figure 59 on the 
following page. The purpose of this simultaneous STD experiment is to ensure no false 
positives occur as a result of directly exciting the ligand. A lack of signals in the difference 
spectrum (in blue) indicates the ligand is not directly excited, and the presence of peaks in 
the difference spectrum in Figure 58 is indeed due to successful ligand-protein binding, 







Ligand 29-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum (Top), 
Ligand 29 on-resonance control spectrum (Middle), difference spectrum (Bottom) 
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3.6.2.3 Ligand 29 CPMG NMR 
CPMG NMR is the final protein-ligand affinity determining experiment. CPMG NMR 
works by measuring spin-spin T2 relaxation times and applying a series of spin-echo pulse 
elements to transverse magnetization76 in order to detect ligand exchange processes. In 
practice, a CPMG spectrum of the ligand sample is taken (which has a fixed relaxation 
time) and compared to the CPMG spectrum of the ligand + protein containing sample. 
Variability in T2 relaxation times as a result of successful magnetisation corresponds to 
successful ligand binding, which is indicated by reduced peak signals on the protein-ligand 
NMR spectrum77. 
 







Ligand 29 STD NMR Spectra, Reference Proton 1D spectrum (Top), Ligand 29 on-
resonance control spectrum (Middle), difference spectrum (Bottom) 
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As can be seen, the reduced peak intensities as seen in the protein-ligand CPMG spectrum 
indicated in blue suggest successful binding determined by CPMG NMR. In addition to 
determination by waterLOGSY NMR and STD NMR, Ligand 29 is confirmed as a 
successful hit to the TbrPDEB1 target by NMR protein-ligand interactions as well as 














Ligand 29-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D spectrum (Top), 
Ligand 29 Control CPMG spectrum (Middle), Ligand-Protein CPMG spectrum 
(Bottom) 
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3.6.2.4 Ligand 27 waterLOGSY NMR 



































Ligand 27-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
spectrum (Top), Ligand 27 Control WaterLOGSY spectrum (Middle), Ligand-
Protein WaterLOGSY spectrum (Bottom) 
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3.6.2.5 Ligand 27 STD NMR 
Furthermore, Ligand 27 also appears as a non-binder in STD NMR: 
As can be seen, the on-resonance and off-resonance STD spectra cancel out, giving a flat 
















Ligand 27-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 
(Top), Ligand 27 on-resonance control spectrum (Middle), difference 
spectrum (Bottom) 
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3.6.2.6 Ligand 27 CPMG NMR 




















This is determined due to a lack of signal reduction in the ligand-protein CPMG spectrum 
seen in blue compared to the reference spectrum in green. 
 
To summarise: alongside Ligand 29, Ligand 1 is the only other ligand with triple NMR 
protein-ligand interaction confirmations. Ligand 29 was an expected hit outcome as it was 
the strongest hit observed in the Biochemical assays as previously shown. Ligand 1 has 
also shown a binding affinity to the TbrPDEB1 target protein following the NMR screen, 
despite showing no inhibition in the Biochemical assays. However, binding of a particular 
ligand occurring does not necessarily mean that ligand is also capable of target inhibition. 
In the case of Biochemical assays, it is likely that Ligand 1 is not a competitive enough 
inhibitor against the cAMP substrate and therefore cannot displace it from the binding site, 
which is a possible explanation for the lack of measured inhibition. 
 
Figure 63: 
Ligand 27-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D spectrum 
(Top), Ligand 27 Control CPMG spectrum (Middle), Ligand-Protein CPMG 
spectrum (Bottom) 
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Surprisingly, Ligand 27 did not appear as a hit following the NMR techniques used, 
despite being identified as a hit in the Biochemical assay experiments. As previously 
presented, Ligand 27 proved to be an optimal ligand hit, as it forms the vital Q-Switch 
binding as shown by X-Ray crystallography and also has a small measured inhibition 
towards the TbrPDEB1 target as shown by the Biochemical assays. However, as discussed, 
these particular NMR experiments are strictly for weakly-binding ligands with a low 
binding affinity towards the target, as rapid dissociation from the bound and unbound state 
is required in order to transfer magnetisation. Hence, Ligand 27 not showing up as a hit in 
these particular experiments does not necessarily mean it is a weak binder by NMR. On the 
contrary, it is possible that it binds too tightly to the TbrPDEB1 target in order to satisfy 
the required fast dissociation, resulting in a false negative occurring. Further 
experimentation on Ligand 27 is required to put this hypothesis to the test.  
 
3.6.3 Ligand 27 competitive STD NMR 
An additional protein-ligand STD experiment was repeated to further determine Ligand 27 
as a binder by NMR. The experiment was repeated as described in section 2.8.3 with a 
weak binding ligand. Hence, the appropriate samples were prepared in the case of Ligand 




Ligand 1-TbrPDEB1 STD Competitive NMR Spectra, Reference Proton 1D 
spectrum (Top), Ligand 1 on-resonance control spectrum (Middle), difference 
spectrum (Bottom) 
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As can be seen, the weakly binding Ligand 1 shows binding affinity to TbrPDEB1 by STD 
NMR. Adding a further 0.5mM of Ligand 27 to the samples would assist in determining 
whether Ligand 27 is indeed a strong-binding ligand as predicted, indicated by a decrease 
in peak intensity as a result of Ligand 27 displacing Ligand 1 from the substrate binding 












It can be determined from this figure that Ligand 27 is actually not a strong-binding ligand, 
as the Ligand 1 peaks remain present in the difference spectrum as seen in blue. 
 
After further investigation, it was determined that Ligand 27 was unsuccessfully validated 
as a binder by NMR due to poor solubility. As previously mentioned, a lack of peaks on 
the control spectra in the case of Ligand 27 waterLOGSY, STD and CPMG experiments 
causes the difference spectra measured to be false negatives as they cannot be compared to 
the control. Proton 1D spectra of Ligand 27 were once again taken in DMSO and in 




Ligand 1+27-TbrPDEB1 Competitive STD NMR Spectra, Reference Proton 
1D spectrum (Top), Ligand 1+27 on-resonance control spectrum (Middle), 
difference spectrum (Bottom) 






























Ligand 27 in DMSO Proton 1D 
Figure 67: 
Ligand 27 in phosphate buffer Proton 1D 
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It can be deduced from the seen 1D spectra that Ligand 27 is in fact insoluble in phosphate 
buffer, explaining the lack of peaks in the control spectra on the previously shown ligand-
protein affinity NMR spectra. However, peaks appear to be present in the reference 
spectra, meaning that Ligand 27 is soluble in the presence of TbrPDEB1 protein. A lack of 
oxygen atoms or lone pairs on the Ligand 27 methyl-triazolo-quinazoline structure make 
hydrogen bonding extremely difficult, resulting in very poor solubility in water, making it 
a poor lead candidate compared to Ligand 29, which is evidently far more soluble due to 
the sulphonamide oxygen atoms and the nitrobenzene negative charge.   
 
3.7 Substructure Similarity Search 
In collaboration with Lorena Zara, a PhD student from VU University in Amsterdam, a 
ROCS79 shape similarity search follow-up was performed on Ligand 29. ROCS is a 
powerful virtual screening method used to identify potentially active compounds by shape 
comparison79. Hence, an SAR by catalogue (Structure-activity relationship) search of 
Ligand 29 was performed cross referenced with commercially available ligands from 
ZINC80 ± a database consisting of millions of purchasable compounds available for virtual 
screening.  
 
10 compounds with a ROCS ComboScore of above 1.0 were identified. A ROCS 
ComboScore is a rating system used to rank compounds by their shape similarity to the 
original compound using a score value between 0 and 2. The top 3 structures (compared to 
Ligand 29) are presented in Figure 68 as seen on the following page. The remaining 
structures are seen presented in Appendix 68 ± Appendix 74 in the Appendices. 
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VM_STL367219 (Figure 68-2) is the closest derivative to Ligand 29 (Figure 68-1) with a 
ComboScore of 1.4299. CB_5346663 (Figure 68-3) and EN_Z2157984556 (Figure 68-4) 
also possess a ComboScore of 1.397 and 1.395, respectively. A follow-up project of 
interest may involve performing similar screening experiments on a set of compounds 
identified by this substructure search in order to observe how potency is affected by 
differentiation of certain side chains and functional groups. In turn this would lead to the 
expansion of an active TbrPDEB1 fragment library, which would meet the core aims of 








Ligand 29 (1) ROCS similarity search, VM_STL367219 (2), CB-5346663 (3), 
EN_Z2157984556 (4)  





screening methods in order to validate it for a similarity-search follow up. Ligand 29 has 
been identified as a binder to TbrPDEB1 by X-Ray Crystallography and protein-ligand 
NMR screening, and a low potency inhibitor to TbrPDEB1 through the use of Biochemical 
assay experiments. Despite also possessing a small inhibition towards the drug target at a 
high concentration, this fragment is not deemed suitable for dose response curves or further 
experimentation as previously discussed. However, derivates of the active scaffold have 
been identified which would be of interest in a follow-up project. Another follow-up 
experiment of interest could include the screening of the fragment library against hPDE4d 
by X-Ray Crystallography in order to compare and contrast the key differences between 
the binding modes and interactions of the compounds of interest against the two different 
targets. Additionally, repeating the X-Ray Crystallography screening of the fragment set 
used in this project using the XCHEM approach as previously discussed would also be of 
interest and useful in the optimisation of the XCHEM protocol to aid in identifying high 
affinity ligands using this platform. 
 
Fragment screening has proven to be an effective means of hit identification for the 
discovery of inhibitors against a validated drug target. Being able to quickly assess the 
interactions and potency of low molecular weight fragments against a particular drug target 
is undoubtedly beneficial, allowing for quick identification of ideal compound scaffolds by 
being able to categorise and differentiate fragments from non-binders to potential leads. A 
clear example of this is seen in the case of a previously cited article by AR. Blazeer et al33 
as well as other similar scientific research papers referenced within this report discussing 
the research of the PDE4NPD project. Fragment-based and high-throughput screening as 
well as hit-to-lead follow up experiments resulted in the synthesis of a number of potent 
TbrPDEB1 inhibitors such as NPD-001 and NPD-008, the latter also consisting of partial 
selectivity towards the TbrPDEB1 target as was previously discussed throughout this 
report. Despite ideal potency being met, selectivity remains the biggest issue in identifying 
an ideal compound for the treatment of HAT. 
 
Table 16 on the following page shows a brief comparison overview of the screening 
techniques used in this research project. 




When attempting to identify novel fragments, it is of upmost importance to use as many 
resources and techniques as possible, as each screening method possesses certain 
advantages and disadvantages and indeed yield different results; Much more can be learnt 
about the interaction of a compound when using a wide variety of techniques. 
Additionally, being able to compare results from different screening methods and 
observing overlaps and agreements, as can be seen in the example of Ligand 29 being 
identified as a binder by Biochemical assays and protein-ligand NMR, is greatly beneficial 
and can increase confidence and validation for a particular scaffold.  
 
The identified binder to TbrPDEB1 within this research project through the use and 
understanding of various screening approaches essential for drug discovery is without a 
doubt a success, and has led to all of the project aims to have been met. To conclude, 








NMR Biochemical Assays 







Yes Yes/No No 
Binding affinity No Yes/No Yes 
Cost High Medium Low 
Number of 
compounds per screen 
10-100 100-1000 1000-10,000 
Table 16: 
Brief overview comparison of screening techniques used 
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Appendix 2 ± Ligand 1 Proton QC 
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Appendix 6 ± Ligand 5 Proton QC 
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Appendix 8 ± Ligand 8 Proton QC 
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Appendix 10 ± Ligand 10 Proton QC 
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Appendix 12 ± Ligand 12 Proton QC 
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Appendix 14 ± Ligand 14 Proton QC 
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Appendix 24 ± Ligand 24 Proton QC 
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Appendix 26 ± Ligand 26 Proton QC 
 
 
Appendix 27 ± Ligand 28 Proton QC 
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Appendix 28 ± Ligand 30 Proton QC 
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Note that the following structure density maps are not fully refined and can undergo 
further modifications. 

































153 | P a g e  
 



































154 | P a g e  
 



































155 | P a g e  
 



































156 | P a g e  
 
Appendix 40 ± Phosphate buffer solvent used to make up Protein-Ligand solutions Proton 
1D NMR 
 
Appendix 41 - Ligand 1-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 1 Control WaterLOGSY spectrum (Middle), Ligand-Protein 
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Appendix 42 - Ligand 1-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 















Appendix 43 ± Ligand 1-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D spectrum 
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Appendix 44 - Ligand 3-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 3 Control WaterLOGSY spectrum (Middle), Ligand-Protein 
















Appendix 45 - Ligand 3-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 
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Appendix 46 ± Ligand 3-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D spectrum 
















Appendix 47 - Ligand 4-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 4 Control WaterLOGSY spectrum (Middle), Ligand-Protein 
















160 | P a g e  
 
Appendix 48 - Ligand 4-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 















Appendix 49 - Ligand 4-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D spectrum 
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Appendix 50 - Ligand 6-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 6 Control WaterLOGSY spectrum (Middle), Ligand-Protein 















Appendix 51 - Ligand 6-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 
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Appendix 52 - Ligand 6-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D spectrum 
















Appendix 53 - Ligand 9-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 9 Control WaterLOGSY spectrum (Middle), Ligand-Protein 
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Appendix 54 - Ligand 9-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 
















Appendix 55 - Ligand 9-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D spectrum 
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Appendix 56 - Ligand 12-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 12 Control WaterLOGSY spectrum (Middle), Ligand-Protein 















Appendix 57 - Ligand 12-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 
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Appendix 58 - Ligand 12-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D 
















Appendix 59 - Ligand 17-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 17 Control WaterLOGSY spectrum (Middle), Ligand-Protein 
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Appendix 60 - Ligand 17-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 














Appendix 61 - Ligand 17-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D 
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Appendix 62 - Ligand 22-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 22 Control WaterLOGSY spectrum (Middle), Ligand-Protein 















Appendix 63 - Ligand 22-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 
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Appendix 64 - Ligand 22-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D 

















Appendix 65 - Ligand 23-TbrPDEB1 waterLOGSY NMR Spectra, Reference Proton 1D 
Spectrum (Top), Ligand 23 Control WaterLOGSY spectrum (Middle), Ligand-Protein 
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Appendix 66 - Ligand 23-TbrPDEB1 STD NMR Spectra, Reference Proton 1D spectrum 















Appendix 67 - Ligand 23-TbrPDEB1 CPMG NMR Spectra, Reference Proton 1D 
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Appendix 74 ± CD_8010-5614:TT_ST4055854:VM_STK762870 ROCS Similarity search, 
ComboScore 1.321 
 
 
